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ABSTRACT 
 
Mitigating Disuse Bone Loss: Role of Resistance Exercise and Beta-Adrenergic 
Signaling.  (May 2010) 
Joshua Michael Swift, B.S., The Pennsylvania State University 
Chair of Advisory Committee: Dr. Susan A. Bloomfield 
 
Mechanical loading is an integral component to maintaining bone mass during 
periods of disuse (i.e. bedrest or casting) or reduced weightbearing activity.  Recent data 
has shown a direct relation between the sympathetic nervous system (SNS) and bone 
metabolism, however the underlying mechanisms responsible for this relationship are 
unknown.  Furthermore, the role that beta adrenergic stimulation during disuse has on 
cancellous bone mass and microarchitecture have yet to be defined.  The central 
hypothesis of this research is that resistance exercise and beta-1 adrenergic (Adrb1) 
receptor agonist administration attenuate disuse-associated reductions in metaphyseal 
bone during 28 days of rodent hindlimb unloading (HU).  
 Study one determined whether an eccentric- (ECC) or combined 
isometric+eccentric- (ISO+ECC) based contraction paradigm, engaged during hindlimb 
unloading (HU), mitigates losses in musculoskeletal mass and strength.  Both simulated 
resistance training (SRT) protocols inhibited reductions in disuse-sensitive cancellous 
bone mass and maintained plantarflexor muscle strength. 
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Study two determined whether combining the anabolic effects of SRT with the 
anti-resorptive effects of alendronate (ALEN) during HU positively impacts cancellous 
bone in an additive or synergistic fashion.  ALEN significantly inhibited the anabolic 
response of cancellous bone to SRT during HU. 
Study three determined whether an Adrb1 receptor agonist (dobutamine; DOB) 
mitigates disuse-associated losses in bone mass and formation rate (BFR) during HU.  
DOB administration significantly blunted reductions in bone mineral density (vBMD) by 
maintaining cancellous BFR.   
 Study four determined if Adrb1 receptor agonist administration during HU 
results in an attenuation of osteocyte apoptosis within cancellous bone and whether this 
relates to a decrease in Bax/Bcl-2 mRNA content ratio (pro- and anti-apoptotic proteins).  
HU significantly increased cancellous bone osteocyte apoptosis and Bax/Bcl-2 mRNA 
content ratio, which was reduced by the administration of DOB.   
Collectively, these are the first studies to assess the role of beta-1 adrenergic 
signaling and resistance exercise in mitigating disuse-induced loss of cancellous bone 
mass in rodents.  The long term goals of this research are to understand the exact 
molecular mechanisms by which both Adrb1 signaling and high intensity resistance 
exercise provide beneficial bone effects during prolonged periods of disuse and to apply 
these findings to current osteoporosis research. 
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CHAPTER I 
INTRODUCTION 
  
During normal weightbearing, bone formation (osteoblasts) and bone resorption 
(osteoclasts) remain equal, and the skeleton is in a state of balance.  During periods of 
decreased skeletal loading, bone formation and resorption become uncoupled, with 
increased resorption and decreased formation leading to a net loss of bone mass.  This 
reduction in skeletal mass, if continued over a prolonged period of time, leads to 
osteopenia or osteoporosis and significantly increases the risk of skeletal fracture.    
Outside of the realm of microgravity, periods of disuse or reduced mechanical 
loading are encountered by a large number of persons and are, therefore, of great 
importance for continued investigations.  Individuals exposed to prolonged bed rest, 
limb immobilization, or spinal cord injury give clinical relevance to the accelerated bone 
loss associated with spaceflight.  However, understanding the mechanisms underlying 
the processes of skeletal tissue loss during disuse and aging have yet to be determined, 
and many similarities between bone loss in these two models do exist.  Therefore, 
research aimed at determining the mechanisms involved in disuse-associated reductions 
in skeletal loss will provide essential insight into age-related decrements in bone mass 
and osteoporosis. 
____________ 
This dissertation follows the style of Journal of Bone and Mineral Research. 
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Bisphosphonates are well established as the leading drugs for the treatment of 
osteoporosis and other skeletal diseases characterized by increased bone resorption. 
Alendronate (ALEN), a nitrogen-containing bisphosphonate, has been approved by  
NASA for in-flight experiments.  Alendronate inhibits bone resorption and ultimately 
contributes to osteoclast apoptosis, thereby maintaining skeletal mass and strength.  
Additionally, ALEN is a proven agent in minimizing bone loss due to estrogen 
deficiency and disuse in rats.   
 Resistance exercise is an anabolic agent proven to stimulate bone growth, even 
during periods of bed rest and disuse.  The high strains imparted on bone, typically 
encountered during high intensity resistance exercise, activate mechanical and chemical 
signaling within bone and ultimately lead to “modeling activity.”  As of yet, no animal 
studies have successfully inhibited reductions in cancellous bone mass and formation 
using resistance exercise protocols.  Furthermore, no studies have addressed the effects 
that combining bisphosphonate treatment with a resistance exercise protocol, completed 
during disuse, has on disuse-sensitive cancellous bone. 
The sympathetic nervous system (SNS) has been shown to mediate bone 
metabolism.  However, the exact role that beta-1 adrenergic (Adrb1) receptors have in 
this process has not been elucidated.  Although stimulation of the SNS has been 
documented to increase bone resorption, resulting in reduced cancellous bone mass and 
microarchitecture, this has been primarily attributed to stimulation of Adrb2 receptors.  
The role that Adrb1 receptor stimulation during reduced mechanical loading has on 
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disuse-sensitive cancellous bone is important to further understanding the underlying 
mechanisms responsible for bone loss. 
 In the first study included in this dissertation (Chapter III), we investigated the 
effects of two separate simulated resistance training (SRT) protocols, engaged during 
rodent hindlimb unloading, on bone and muscle mass and strength.  Results from this 
investigation demonstrated that high-intensity muscle contractions, independent of 
weightbearing forces, can effectively mitigate losses in muscle strength and provide a 
potent stimulus to bone during prolonged disuse.  Based on results from the first study, 
we hypothesized that by adding an anti-resorptive agent, alendronate (ALEN; 
bisphosphonate), to an anabolic stimulus, SRT, disuse-associated reductions in 
cancellous bone formation and microarchitecture would be completely inhibited.  In the 
second study (Chapter IV), we investigated the individual and combined effects of a 
reduced volume and intensity of SRT and ALEN treatment during HU on cancellous 
bone parameters.  Results from this investigation further demonstrate the anabolic effect 
of a low volume of high intensity muscle contractions during disuse and suggest that 
both bone resorption and formation are suppressed when SRT is combined with 
bisphosphonate treatment.  Furthermore, this study describes the potential inhibitory 
effects of ALEN treatment on cancellous bone’s response to SRT during rodent 
hindlimb unloading. 
In the third study (Chapter V), we evaluated the effects of a beta-1 adrenergic 
(Adrb1) agonist, dobutamine (DOB), on unweighted tibiae and femoral bone content, 
density, area, and strength during 28 days unloading.  DOB administration during HU 
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effectively attenuated significant declines in total volumetric bone mineral density 
(vBMD) at the proximal tibia by mitigating associated decrements in bone formation.  
The significant positive effects of DOB on unweighted bone are not observed in animals 
experiencing normal gravitational loading and provide evidence for the importance of 
Adrb1 signaling in maintaining bone mass.  Based on results from the third 
investigation, we wanted to determine if the positive effects of DOB on unweighted 
cancellous bone resulted in enhanced metaphyseal microarchitecture and were directly 
related to reductions in osteocyte apoptosis.  In the fourth study (Chapter VI) we tested 
the effects of an Adrb1 agent on osteocyte apoptosis and expression of a pro- and anti-
apoptotic protein (Bax, Bcl-2) in unloaded bone.  Results from this investigation 
illustrated the effectiveness of DOB treatment during HU to mitigate reductions in 
cancellous bone microarchitecture and increases in osteocyte apoptosis, perhaps by 
inhibiting increased Bax/Bcl-2 mRNA content. 
 Results of these investigations highlight the potential ability of high-intensity 
muscle contractions to completely abolish disuse-associated reductions in cancellous 
bone mass, formation, and deleterious changes in microarchitecture, and further 
emphasize the role that both resistance exercise and bisphosphonate treatment have to 
inhibit osteocyte apoptosis.  In addition, these studies demonstrate the dynamic role that 
beta-1 adrenergic agonist signaling has on maintaining cancellous bone during periods of 
reduced weightbearing or unloading.  Hence, these findings have important implications 
for humans experiencing extended periods of reduced weightbearing activity. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
Bone Remodeling and Modeling in the Adult Skeleton 
Skeletal remodeling, occurring throughout the lifetime of a mammal, is defined 
as the collaborative and sequential efforts of a BMU (bone multicellular unit).  BMU’s 
operate on periosteal, endosteal, and trabecular surfaces, as well as within cortical bone 
by replacing old with new bone.  Osteonal BMU’s originate on the periosteal or 
endosteal surfaces of bone, or along the walls of Haversian canals, and are activated by 
chemical, mechanical, or electrical signals.  The process of bone remodeling is based 
upon the coupled action of bone-resorbing cells (osteoclasts) and bone-forming cells 
(osteoblasts).  Osteoblasts, as well as chondrocytes, adipocytes, fibroblasts, and 
myoblasts, differentiate from mesenchymal stem cells (1).  Osteoclasts, however, are 
derived from the hematopoietic mononuclear lineage (2).  The primary functions of the 
remodeling cycle include: (1) the preventative maintenance of mechanical strength 
through replacement of fatigued bone by new, mechanically sound bone, and (2) 
maintenance of mineral homeostasis by providing access to stores of calcium and 
phosphorous.   
 There are 4 basic phases of the remodeling cycle, which include (1) activation, 
(2) resorption, (3) reversal, and (4) formation.  Activation involves the recruitment of 
multinucleated osteoclast precursors from cells in the monocyte-macrophage lineage.  
Most remodeling is likely random, but can be targeted towards specific sites that need to 
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be repaired.  Pre-osteoclasts, from hematopoietic stem cells, affix themselves to the bone 
matrix through binding between integrin receptors and organic matrix, creating a sealing 
zone.  Osteoclasts are then able to create a bone-resorbing compartment between itself 
and the bone matrix.  Activation of osteoclasts is regulated by local cytokines like 
RANKL, IL-1 and IL-6 (3,4). 
 Resorption, the second phase of remodeling, involves the catabolic actions of 
osteoclasts.   Osteoclasts are multinucleated, macrophage-like cells that attach to the 
bone surface, form a peripheral seal, and break down bone within a sealed area by means 
of enzymes or chemicals (1).  The osteoclast’s membrane transfers protons to the 
resorbing compartment (attached to bone) lowering its pH to 4.  This compartment 
becomes acidified by the secretion of lysosomal enzymes like TRAPC and cathespin K, 
which dissolves and digests the mineral and organic phases of the matrix.  This 
resorption of bone creates a saucer-shaped cavity, called Howship’s lacunae.   
The process of bone resorption ends with osteoclast apoptosis and the reversal 
phase begins.  During reversal, signals are sent out to “summon” osteoblasts into the 
newly formed resorption cavities to replace removed bone.  Without efficient coupling 
mechanisms, remodeling would result in net bone loss.  There are two theories of 
coupling signals: (1) osteoclasts release growth factors from bone matrix during 
resorption, which attract osteoblast precursors and stimulate osteoblast proliferation and 
differentiation; or (2) strain-regulated theory: strain levels are lower ahead of osteoclasts 
and higher behind them (in BMU as it moves through bone).  Osteoblasts are activated 
in response to high strain, and osteoclasts are activated in response to reduced strain. 
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Following reversal, formation of new bone occurs.  Formation is a two step 
process, whereby osteoblasts synthesize organic matrix and then regulate its 
mineralization.  Osteoblasts mineralize organic matrix by deposition of Ca
2+
 and 
phosphate ions.  After completion of their bone formation function, osteoblasts have 
three cell fates: (1) die by apoptosis, (2) become entombed in the mineralizing matrix as 
osteocytes, or (3) remain on the surface as bone lining cells.  Osteocytes maintain 
contact with each other and cells on bone surface via gap junctions between cytoplasmic 
processes that extend through canaliculae.  Osteocytes become part of network which 
can sense changes in mechanical properties surrounding bone and transmit this 
information to cells on bone surface (i.e. osteoblasts) to initiate or regulate bone 
remodeling when necessary. 
Modeling differs from remodeling, as this process is not defined by the 
coordinated actions of osteoblasts and osteoclasts.  Instead, modeling involves the 
shaping or reshaping of bones by independent actions of these cells.  During modeling, 
bone formation is not coupled to resorption, and vice versa.  Modeling occurs during 
growth or, in an adult skeleton, in response to increased mechanical loading.  
Additionally, modeling occurs less frequently than remodeling in adults, particularly in 
cancellous bone. 
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Disuse Bone Loss 
Spaceflight Effects on Bone (Human)  
Mechanical loading is an integral component to maintaining bone mass during 
periods of disuse (i.e. bedrest or casting) or reduced weightbearing activity.  In-flight 
measures of bone mass and geometry are not possible to obtain, therefore serum and 
urine biomarkers of bone formation and resorption have become useful pieces of 
evidence to our understanding how bone responds to microgravity.  Early studies from 
Skylab missions (1973-1974) sought to determine transient changes in bone metabolic 
biomarkers during 28, 59, and 84 days of space flight.  Data from these missions 
demonstrated nearly 2-fold increases in-flight in urinary excretion of bone resorption 
markers type 1 cross-linked N-telopeptide of  (NTX), deoxypyridinoline (DPD), and 
pyridinoline (PYD), and hydroxyproline vs. pre flight values (5,6).  Later investigations 
on MIR cosmonauts extended results from these Skylab missions.  Extensive 
microgravity exposure (up to 180 days) significantly reduced bone alkaline phosphatase 
(BAP; bone formation biomarker) and increased DPD and type 1 cross-linked C-
telopeptide (CTX; bone resorption biomarkers) up to 80% (7-10).  A study by Smith and 
colleagues (10) demonstrated no change in BAP or osteocalcin during 180 days of space 
flight.   However, these authors noted a significant loss of Ca
++
 absorption (~250mg/d) 
during microgravity.  Assessment of changes in biomarkers of bone metabolism pre vs. 
post-flight, demonstrated that, although bone formation markers were unchanged during 
microgravity exposure, osteocalcin and BAP were significantly increased post-flight 
(11).   
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Although bone biomarkers provide readily accessible data in-flight data (from 
urine or serum), their amounts vary considerably from day to day and from subject to 
subject (12).  For this reason, more reliable ground-based measures of bone mass and 
geometry were necessary to document skeletal changes attributable to space flight.  Long 
duration exposure to microgravity leads to an accelerated loss of bone mass (~1-
2%/month) and results in osteopenia (13,14).  Vico and colleagues (14) completed 
peripheral quantitative computed tomography (pQCT) scans on tibiae and radii of 
cosmonauts before and after long-duration MIR missions and demonstrated that 
prolonged microgravity exposure (6+ months) results in greater reductions in cancellous 
than cortical bone mineral density (BMD), and that these reductions in tibia cancellous 
BMD are not fully restored by 6 months of recovery.  Furthermore, microgravity 
exposure affects bone mass in weightbearing (i.e. lower body) bones only.  Recent data 
gathered from crew members on the International Space Station (ISS) illustrates the 
significant losses of bone mineral density (BMD) and geometry of the femoral neck 
(15).  Dual-energy x-ray absorptiometry (DXA) and QCT scans were taken on 14 ISS 
astronauts before and after 4-6 month missions.  Data from this investigation 
demonstrated that the greatest reductions in areal BMD (aBMD) and trabecular 
volumetric BMD (vBMD) occurred at the hip at a rate of 1.4-1.5% and 2.2-2.7%/month, 
respectively (15).  A subsequent study by Lang and colleagues (16) illustrated a 
significant increase in estimated fracture risk during 4.5-6 month ISS missions that 
remains even 1 year after returning to Earth.  Pre- and post-flight peripheral pQCT scans 
were administered to astronauts serving a single 4-6.5 month mission aboard ISS, and 
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finite element models (FEM) of these scans were completed to assess estimated 
proximal femoral strength during stance or a fall onto the posterolateral aspect of the 
greater trochanter.  For those crew members experiencing the greatest bone loss, 
reductions in modeled proximal femur strength after a microgravity exposure 
approached the estimated lifetime loss in stance strength for Caucasian women (17).  
Furthermore, lack of recovery of BMD in ISS and MIR crew members has been 
documented 6 months post-flight (14), with indications that it may not be fully restored 
for 3 years (18).   
 Taken together, these data suggest that microgravity results in reduced bone 
mass, which is attributable to increased bone resorption and decreased (or unchanged) 
bone formation and negative calcium balance (in-flight).  Furthermore, these reductions 
in bone mass put astronauts at increasingly greater risk of fracturing their hip upon 
return to Earth’s 1-gravity atmosphere.  Most importantly, losses in bone typical of 
exposure to microgravity are not fully restored by an equal amount of recovery time (i.e. 
6 months).  
 
Simulating Bone Loss with Spaceflight in Rodents: Hindlimb Unloading/Tail Suspension 
 The rodent hindlimb unloading (HU) model was developed by Emily Morey-
Holton in the 1970’s to most effectively mimic the effects of spaceflight on multiple 
systems of the body (19).  This model was the first to successfully model microgravity-
induced alterations in cardiovascular, muscular, and skeletal tissues, all the while not 
overly stressing the animal.  The HU model has become the gold-standard Earth-based 
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model to simulate microgravity effects, as it allows the animal ambulation using only the 
forelimbs, unloads the hindlimbs without paralysis, and produces cephalic fluid shifts 
(20).  Furthermore, ground-based studies using the HU model provide a more efficient 
avenue to continue to study the effects of microgravity on the body, in comparison to 
actual shuttle experiments, which are costly and extremely competitive.  
 Similar to the effects of microgravity in humans, rodent hindlimb unloading 
significantly reduces cancellous bone within the metaphyses of the unweighted femur 
and tibia (14,21).  The effects of HU in adult male rats are compartment-specific, as 28 
days of unloading primarily impacts cancellous and not cortical bone sites (21).  HU 
results in significant reductions in disuse-sensitive cancellous bone mass, architecture 
and material properties, due to early increases in bone resorption followed by prolonged 
depressions in bone formation rate (BFR) (21-24).  These reductions in cancellous bone 
mass are accounted for by decreased trabecular thickness (25-27) and number (27) and 
increased trabecular spacing (24).   
 
Resistance Exercise Effects on Skeletal Tissue 
It has been well established that bone responds to increased and reduced 
mechanical loading in opposing manners.  Resistance exercise (RE) training incurs an 
integrated physiological response typical of intense exercise (e.g., increased sympathetic 
nervous system outflow, blood flow, and IGF-1 production), but which has not been 
demonstrated with other models of mechanical loading (28-31).  Squats, a lower-body 
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form of RE, produces significant lower leg muscle hypertrophy and increased skeletal 
muscle protein synthesis (32-34).   
 Resistance exercise that includes eccentric contractions provides an anabolic 
stimulus for both skeletal muscle and bone in human and rodent models (35-38), and has 
generally proven more effective in promoting increased bone and muscle mass than 
endurance exercise protocols such as running.  Furthermore, eccentric contractions 
(during muscle lengthening) generate larger muscle forces than do concentric 
contractions (muscle shortening), providing greater increases in BMD (36).   
 
Resistance Exercise Effects on Bone (Humans) 
In humans, bone responds to increased mechanical stress, evidenced during high-
impact and resistance exercise (RE), and has demonstrated the ability to increase lumbar 
spine and femoral neck (FN) bone mass and strength (39-41).  Resistance exercise 
provides the necessary load to increase bone mass in healthy individuals and prevents 
skeletal losses in estrogen deficient women, thereby decreasing the risk of fracture 
during a fall (30,42-45).  Furthermore, high-intensity RE (39,46) elicits a greater 
anabolic response on bone than lower-impact activities like running or walking (47), 
making it an attractive countermeasure to inhibit bone loss encountered in persons 
experiencing reduced activity. 
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Modeling Resistance Exercise Effects on Bone in Small Animal Models 
Animal studies demonstrate similar results, as high-intensity RE and jump 
training provide greater anabolic stimulus to bone than repetitive, low-load, high-
frequency exercise (i.e. running) (48,49).  Drop training, whereby an animal is dropped 
from a set height and lands with high amount of force on its hindlimbs, results in greater 
proximal tibia total and cancellous volumetric bone mineral density (vBMD), (as a 
consequence of greater trabecular thickness (TbTh) compared to ambulatory controls) 
(50,51).  Jump exercise, experienced when an animal jumps vertically in response to a 
visual stimulus, in rats and mice leads to greater bone volume (BV/TV) and osteoblast 
activity (MAR) at cancellous-rich bone sites (48,49) as well as increased cortical bone 
mass and strength (50,52).  Furthermore, jumping with weighted backpacks (i.e. jump 
RE) has demonstrated the ability to increase trabecular thickness (TbTh), trabecular 
number (TbN), and bone volume in the proximal tibia (38). 
 
Resistance Exercise Effects on Bone During Extended Bed Rest (Human) 
Only a few long-term bed rest investigations have successfully mitigated bone 
loss with exercise paradigms.  Combined supine flywheel resistive and treadmill 
exercise during 90-day bed rest in young men attenuates reductions in trochanter and hip 
BMD (53).  Vigorous resistance training during 17-week bed rest increased lumbar spine 
and diminished reductions in total hip BMD, as well as attenuated losses of leg muscle 
masses and strength compared with bed rest controls (54).  These initial studies provide 
promising data suggesting that losses in skeletal BMD, at sites where greatest bone loss 
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occurs during disuse, can be attenuated if a high-intensity resistance exercise training 
program is begun immediately upon initiation of unloading. 
 
Applying Resistance Exercise During Rodent Hindlimb Unloading 
Previous investigations have sought to define the osteogenic effect of mechanical 
loading during periods of disuse.  Rubin et al (55) ,employing low-magnitude, high-
frequency loads, found that 10min/d of loading was effective at maintaining metaphyseal 
bone volume (BV/TV) and did attenuate losses in bone formation at the proximal tibia.  
More recent studies have utilized electrical stimulation as a countermeasure to disuse-
induced bone loss.  Transcutaneous stimulation of the thigh, producing peak strains of 
~200, did not effectively prevent disuse osteopenia in hindlimb unloaded rodents, but 
did reduce tibial bone loss (56).  A novel rodent resistance exercise device using 
flywheel technology was used by Fluckey et al (57) to demonstrate the effects of 
maximal voluntary squats, performed during suspension, on changes in metaphyseal 
bone mass.  The flywheel exercise protocol maintained distal femur BMD and inhibited 
unloading-induced losses in bone mass at this site.   Lam and Qin (58) recently 
demonstrated the beneficial effects of high frequency electrical stimulation of the leg 
musculature on bone during disuse.  Although this treatment did effectively mitigate 
losses of cancellous bone volume in the unloaded distal femur, there was no 
demonstrable effect on bone formation.  These studies provide initial evidence outlining 
the role of resistance exercise in mitigating reductions in metaphyseal bone mass and 
microarchitecture during periods of disuse or unloading. 
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Bisphosphonate Effects on Bone and Disue-Induced Bone Loss 
Pharmacology of Bisphosphonates 
 Bisphosphonates are a class of anti-resorptive drugs which are strongly attracted 
to bone and inhibit osteoclast-mediated bone resorption.  This characteristic makes 
bisphosphonates especially suitable for the treatment of many skeletal diseases all 
characteristic of severe bone loss.  There are two main classifications of 
bisphosphonates: non-nitrogenous and nitrogenous.  All bisphosphonates have a 
common phosphate-carbon-phosphate (P-C-P) moiety as part of their basic structure 
(59).  Attached to the central P-C-P backbone are two side chains (R1 and R2), as shown 
in Figure 1.  Each bisphosphonate differs in its side chains, which are primarily 
responsible for the binding affinity to mineral (R1) and biochemical activity on 
osteoclast enzymatic activity (R2).   
 
 
 
Fig. 1.  Basic structure of a bisphosphonic acid.   
R1 R2
P-OH
OH  O 
HO-P
O  OH 
C
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Bisphosphonate Mechanisms of Action 
 The major effect of bisphonates on the skeleton is the inhibition of the osteoclast-
mediated bone resorption.  The phosphate ends of the bisphosphonate bind to calcium 
hydroxyapetite on the bone surface and are incorporated into bone during remodeling.  
Uptake of bisphosphonates by osteoclasts during remodeling leads to osteoclast 
apoptosis and the inhibition of key enzymes in the mevalonate pathway (also known as 
the HMG-CoA reductase pathway), preventing the generation of lipids necessary for the 
prenylation of small GTPase proteins (60).  This restricts osteoclastic ability to bind to 
and resorb bone, as the ruffled border of the osteoclast is unable to be maintained, 
resulting in significantly reduced bone loss.  Bisphosphoantes work to slow overall bone 
turnover.  Bone remodeling units exit for longer time periods, which results in a greater 
degree of mineralization of skeletal tissue. 
 In addition to inhibiting osteoclast-mediated bone resorption, recent studies 
suggest that osteocytes may be important target cells for bisphosphonates in bone.  Many 
bisphosphonates appear to protect osteocytes (and osteoblasts) from apoptosis (61).  The 
ability of bisphosphonates to inhibit apoptosis in osteocytes contrasts with their ability to 
induce apoptosis in osteoclasts.  The inhibition of osteocyte apoptosis by 
bisphosphonates appears to be mediated by activation of extracellular signal-regulated 
kinases (ERKs) (62).  This dual role of bisphosphonates and potential interaction with 
osteocytes in vivo needs further investigation before the exact mechanisms of 
bisphosphonates’ actions can be fully understood.   
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Alendronate Effects on Skeletal Tissue During Prolonged Human Bed Rest  
Few bed rest investigations on the effects of alendronate (ALEN) have attempted 
to elucidate the mechanics of this bisphosphonate’s action on bone.  Ruml and 
colleagues (63) administered 20 mg/day of ALEN to healthy males during 3 weeks of 
bed rest and observed a reduction in urinary calcium excretion as compared to controls.  
The only other bed rest study investigating the anti-resorptive capabilities of alendronate 
was by Le Blanc and colleagues (64).  A dose of 10 mg/d of ALEN was administered 
daily to eight male subjects during17 weeks of bed rest.  Daily ALEN treatment 
successfully prevented reductions in lumbar spine and femoral neck BMD and 
attenuated increases in urinary markers of bone resorption [cross-linked N-teleopeptide 
of type I collagen (NTX), pyridinium (Pyd), an deoxypyridinium (D-Pyd)].  However, 
ALEN during bed rest resulted in significant reductions in serum markers of bone 
formation (alkaline phosphatase, bone-specific alkaline phosphatase, and osteocalcin), 
which remained unchanged in bed rest subjects not administered ALEN. 
 
Alendronate Effects on Skeletal Tissue During Rodent Hindlimb Unloading  
The effectiveness of alendronate to inhibit disuse-induced bone loss has been 
demonstrated in numerous rodent hindlimb unloading investigations.  Alendronate (100 
g/kg/d), administered prior to HU, prevented reductions in total and proximal tibia 
bone mass and proximal tibia calcium content.  ALEN treatment decreased relative 
osteoclast surface and mitigated reductions in bone formation (26).  Additionally, 
ALEN, administered during 14-day HU, abolished losses in tibia and femur BMD, but 
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was unable to rescue disuse-induced reductions in bone strength (65).  Apseloff et al. 
(66) administered 30 g/kg alendronate during 28 days of unloading and revealed 
significant reductions in osteoid perimeter, cancellous bone formation, and bone 
resorption with bisphosphonate treatment during HU (as compared to controls).  The 
resulting increase in bone mass with alendronate treatment resulted from greater 
inhibition of resorption than from stimulation of formation. 
 
Beta-Adrenergic Signaling in Skeletal Tissue 
Sympathetic Nervous System and Beta-Adrenergic Receptors  
Beta-adrenergic receptor agonists, activated by the sympathetic nervous system 
(SNS), may affect bone metabolism through separate avenues and have opposing effects 
on bone mass.  Three subunits of β-adrenergic receptors (Adrb1, 2, 3) are present in 
tissues within the body and variant effects.  Adrb2 receptors, present in the lungs, cause 
bronchile dilation, and on osteoblasts and osteoclasts, stimulate apoptosis and result in 
diminished bone mass (67,68).  Adrb1 receptors are present on the heart, increasing 
cardiac contractility when activated, and are also present on osteoblasts and osteoclasts 
(69,70).  Activation of β-3 adrenergic receptors, the primary adrenoreceptor on 
adipocytes, results in enhanced lipolysis (71,72).  Adrb1 and Adrb2 receptors are both 
present on osteoblasts, but β-2 adrenergic receptors are the predominant subtype 
(67,68,73-75).   
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Beta-1 Adrenergic Agonist Effects on Bone 
 Dobutamine (DOB) is a non-specific, Adrb receptor agonist with dominant β-1 
adrenergic receptor activity and a small amount of Adrb2 activity (76).  The ability of 
DOB to primarily activate Adrb1 receptors make it an attractive synthetic catecholamine 
to study in coordination with rodent disuse.  To our knowledge, only one study has 
attempted to assess the effects of chronic Adrb1 receptor stimulation on skeletal tissue.  
DOB administered during HU significantly blunted reductions in femoral midshaft 
cortical bone area and cross-sectional moment of inertia (CSMI), as well as mitigated the 
HU-associated decrease in femoral mid-diaphyseal cortical bone mineral apposition rate 
(77).  This preliminary investigation, while lacking mechanisms, provides initial data 
outlining the potential positive effects of increased Adrb1 receptor stimulation during 
disuse. 
 
Beta-2 Adrenergic Agonist Effects on Bone  
Few studies have attempted to define the role that β-2 receptor activation has on 
skeletal tissue, beyond a few investigations completed in female rats.  Adrb2 receptor 
agonist administration leads to increased bone resorption, resulting in reduced cancellous 
bone mass and microarchitecture.  Bonnet and colleagues (78) treated skeletally 
immature, female rats daily (4mg/kg/d) with salbutamol or clenbuterol for 6 weeks.  This 
study demonstrated the significantly deleterious effects of Adrb2 receptor agonists on 
metaphyseal bone, and clenbuterol-treated rats had lower distal femur trabecular number 
(-40%), connectivity (-3-fold), and bone volume (-43%) as compared to controls.  
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Furthermore, although bone formation was not measured, based on data from urinary 
markers the authors concluded the deleterious effects of Adrb2 agonists were related to 
increased resorption and not decreased formation.  A subsequent study by Bonnet and 
colleagues (79) further emphasized the significant reductions in metaphyseal bone in a 
subsequent investigation.  The authors demonstrated that chronic treatment of 
salbutamol or clenbuterol in growing female rats significantly decreased proximal tibia 
and lumbar spine bone volume, trabecular thickness, trabecular number, and 
biomechanical properties.  Furthermore, Bonnet and colleagues (80) verified that 
salbutamol further increases the deleterious effects of estrogen deficiency 
(ovariectomized) on cancellous bone loss in adult rodent.  Additionally, stimulation of 
Adrb2 receptors on osteoblasts increases osteoclast differentiation and activity, resulting 
in increased bone loss (81).   
 
Adrenergic Receptor Knock-Out Mouse Models and Effects on Skeletal Tissue 
A very limited number of in vivo investigations have attempted to systematically 
define the precise roles of β-1 and β-2 receptors and their relation to bone mass.  Adrb2 
receptor knock-out (KO) and Adrb1 receptor KO mice demonstrate a high and low bone 
mass phenotype, respectively, vs. wild type controls (67,82).  Furthermore, reduced bone 
volume in β-less receptor mice (β-1,2,3 KO) is attributed to a marked reduction in 
cancellous BFR (83).  Estrogen deficiency (OVX) further increased the significant 
reductions in metaphyseal bone volume and trabecular number in mice lacking β-
adrenergic receptors as compared to controls.  Finally, Adrb1 receptor deficient mice 
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demonstrated an inability to respond to mechanical loading, whereas Adrb2 receptor and 
wild-type littermates were found to respond normally (82).    
Taken together, these data suggest that the higher bone mass phenotype in Adrb2 
receptor KO mice may be caused by enhanced β-1 adrenergic receptor activity 
stimulating bone formation in the absence of the inhibitory effects of β-2 adrenergic 
receptors on osteoblasts.  Therefore, defining the role that Adrb1 receptor stimulation 
during reduced mechanical loading has on disuse-sensitive cancellous bone is important 
to fully understanding underlying mechanisms responsible for bone loss with disuse. 
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CHAPTER III 
SIMULATED RESISTANCE TRAINING DURING HINDLIMB UNLOADING 
ABOLISHES DISUSE BONE LOSS AND MAINTAINS MUSCLE STRENGTH* 
 
Introduction 
 
 President George W. Bush announced his Exploration Vision for the National 
Aeronautics and Space Agency (NASA) in 2004, proposing lengthy stays at a Lunar 
outpost by 2020 and eventual expeditions to Mars thereafter (84).  Mission success may 
ultimately depend on improvements in our ability to maintain astronaut health and 
functional capabilities during such lengthy trips.  To date, current exercise 
countermeasures (cycle ergometer, treadmill, and resistance exercise device) (85) used 
by crew on the International Space Station (ISS) have not effectively mitigated losses of 
bone mineral density (BMD) or geometry (15), resulting in a significant increase in 
estimated fracture risk that remains even 1 year after returning to Earth (16).  For those 
crew members experiencing the greatest bone loss, reductions in modeled proximal 
femur strength after a 6-month ISS mission approach the estimated lifetime loss in 
stance strength for Caucasian women (16,17).  Furthermore, lack of recovery of BMD in 
ISS and MIR crew members has been documented 6 months post-flight (14), with 
indications that it may not be fully restored for 3 years (18).  In addition to skeletal  
losses, reductions in ISS crew member skeletal muscle volume of the lower leg are  
____________ 
*Reprinted with permission from Swift JM, Nilsson MI, Hogan HA, Sumner LR, 
Bloomfield SA 2010 Simulated resistance training during hindlimb unloading abolishes 
disuse bone loss and maintains muscle strength. J Bone Miner Res 25(3): 564-74. 
Copyright 2010 by John Wiley and Sons, Inc. 
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coupled with significant decrements (nearly 30%) in plantarflexor muscle strength (85). 
These changes in humans exposed to microgravity parallel alterations in bone 
and muscle mass observed during prolonged bedrest (53,54,86,87) and during the more 
severe losses incurred after spinal cord injury (SCI).  Electrical stimulation has been 
utilized in patients with SCI to enable active contractions of the paralyzed lower limbs to 
perform aerobic (cycling) and resistive training.  If this training is started months to 
years after the injury, acting on bone and muscle that is severely compromised by disuse, 
only marginal improvements in muscle strength and BMD in the paralyzed limbs are 
achieved (88-90).  Far more successful is a strategy that starts early after the onset of 
paralysis; stimulated contractions of the plantarflexor muscles begun within 6 weeks of a 
SCI significantly mitigated the loss of muscle torque and contractile speed of the 
paralyzed lower leg, as well as the loss of cancellous bone in the distal tibia (91). 
 The rodent hindlimb unloading (HU) model is a well-established ground-based 
model for investigating disuse effects on bone and muscle (20).  Hindlimb unloading 
results in significant reductions in disuse-sensitive cancellous bone mass, architecture 
and material properties, due to early increases in bone resorption followed by prolonged 
depressions in bone formation rate (BFR) (21-24).  Additionally, skeletal muscle atrophy 
and reduced functional properties (i.e. strength) have been demonstrated as early as 4 
days after HU begins and may remain depressed for some time upon reambulation 
(57,92,93).  To date, no method has successfully prevented deficits in both muscle and 
bone during long duration unloading. 
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Resistance exercise that includes eccentric contractions provides an anabolic 
stimulus for both skeletal muscle and bone in both humans and rodent models (35-38), 
and has generally proven more effective in promoting increased bone and muscle mass 
than endurance exercise protocols such as running.  Eccentric contractions (during 
muscle lengthening) generate larger muscle forces than do concentric contractions 
(muscle shortening), providing greater increases in BMD (36).  Until the launching of 
improved training equipment late in 2008, ISS astronauts were unable to train at the high 
intensities (>70% maximum) demonstrated as osteogenic in land-based studies (94). 
 The purpose of the present investigation was to determine the effectiveness of 
high intensity simulated resistance training (SRT), achieved without weightbearing, in 
maintaining hindlimb muscle and bone (tibia) mass and strength during hindlimb 
unloading in skeletally mature rats.  We sought to maximize the ability of high intensity 
exercise, begun early in the unloading period, to mitigate loss of both muscle and bone 
during unloading and so tested two separate contraction paradigms, an eccentric-based 
(HU+ECC) and a protocol combining both isometric and eccentric contractions 
(HU+ISO/ECC).  We hypothesized that SRT would effectively attenuate disuse-induced 
bone and muscle loss and that doubling muscle contraction time with the addition of an 
isometric component would significantly enhance the effectiveness. 
 
Materials and Methods 
 
Animals and Experimental Design 
Fifty male Sprague-Dawley rats were obtained from Harlan (Houston, TX) at 6 
months of age and allowed to acclimate to their surroundings for 14 days prior to 
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initiation of the study.  All animals were housed in a temperature-controlled (23 ± 2ºC) 
room with a 12-hour light-dark cycle in an American Association for Accreditation of 
Laboratory Animal Care-accredited animal care facility and were provided standard 
rodent chow (Harlan Teklad 8604) and water ad-libitum.  Animal care and all 
experimental procedures described in this investigation were conducted in accordance 
with the Texas A&M University Laboratory Animal Care Committee rules. 
Five experimental groups were studied: (1) cage control (CC, n=12), (2) 
hindlimb unloaded (HU, n=12), (3) HU animals exposed to similar duration of isoflurane 
anesthesia (Minrad Inc., Bethlehem, PA) as trained HU rats (ANHU, n=6), (4) HU 
subjected to eccentric muscle contraction training (HU+ECC, n=10), and (5) HU rats 
subjected to a combined isometric and eccentric hindlimb simulated resistive exercise 
(HU+ISO/ECC, n=10).  Due to the labor-intensive nature of these experiments, it was 
necessary to perform experiments in two successive cohorts of animals.  Rats in cohort I 
(CC, HU, and HU+ECC) and II (ANHU and HU+ISO/ECC) were randomly assigned to 
their respective groups by total vBMD at the proximal tibia metaphysis one day prior to 
study initiation.  HU+ECC and HU+ISO/ECC animals underwent 14 sessions of 
simulated resistive exercise conducted every other day during the 28 day protocol, with 
each session consisting of 4 sets of 5 contractions.  The HU and ANHU groups were 
similarly unloaded for 28 days, whereas the CC animals were allowed normal 
ambulatory cage activity; all animals were singly housed.   
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Hindlimb Unloading 
Hindlimb unloading was achieved by tail suspension as previously described 
(77).  Briefly, while the rat was under anesthesia, the tail was cleaned and dried 
thoroughly.  A thin layer of adhesive (Amazing Goop, Eclectic Products, LA) was 
applied to the proximal half of the tail along the medial and lateral sides.  A standard 
porous tape (Kendall, Mansfield, MA) harness was pressed firmly to the glue and 
allowed to dry (~30 min).  A paper clip was used to attach the animal’s tail harness to a 
swivel apparatus on the wire spanning the top of an 18” x 18” x 18” cage.  The height of 
the animal’s hindquarters was adjusted to prevent any contact of the hindlimbs with the 
cage floor, resulting in approximately a 30° head-down tilt.  The forelimbs of the animal 
maintained contact with the cage bottom, allowing the rat full access to the entire cage.     
Calcein injections (25 mg/kg body mass) were given subcutaneously 9 and 2 
days prior to sacrifice to label mineralizing bone for histomorphometric analysis.  HU 
animals were anesthetized before removal from tail suspension at the end of the study to 
prevent any weight bearing by the hindlimbs.  At necropsy, left soleus, plantaris, and 
gastrocnemius muscles were excised and wet weights were recorded.  Additionally, 
proximal left tibiae were removed, cleaned of soft tissue, and stored at -80°C in PBS 
soaked gauze for mechanical testing, whereas the distal portions of the left tibia were 
stored in 70% ethanol at 4°C for cortical histomorphometry of the TFJ (tibiofibular 
junction) region.   
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Muscle Contraction and Training Paradigms 
 Left plantarflexor muscles from animals in the HU+ECC and HU+ISO/ECC 
groups were trained every other day during 28-day HU using a custom-made rodent 
isokinetic dynamometer, as previously described (Fig 2A) (95).  Animals were 
anesethetized with isoflurane gas (~2.5%) mixed with oxygen while remaining 
suspended, to prevent any weight bearing of the hindlimbs.  Once unconscious, the 
lateral side of the rat’s left leg was shaved and aseptically prepared.  Each rat was then 
placed in right lateral recumbency on a platform, the left foot was secured onto the foot 
pedal, and the left knee was clamped so that the lower leg was perpendicular to the foot 
and the femur and tibia were at right angles to each other.  This was referred to as the 
resting, 0° position.  For isometric contractions, the foot pedal was held fixed in this 
position.  For all contractions, the footplate was rotated in synchronization with muscle 
stimulation by a Cambridge Technology servomotor system (Model 6900) interfaced 
with a 80486 66-MHz PC using custom software written in TestPoint (v.4.0; Capital 
Equipment Corp., Billerica, MA).  In either case, the torque generated around the 
footplate pivot (at the rat’s ankle joint) was measured through the servomotor.  
Plantarflexor muscle stimulation was performed with fine wire electrodes consisting of 
insulated chromium nickel wire (Stablohm 800B, H-ML Size 003, California Fine Wire 
Co.), inserted intramuscularly straddling the sciatic nerve in the proximal thigh region.  
The stimulation
 
wires were then attached to the output poles of a Grass Instruments 
stimulus
 
isolation unit (Model SIU5; Astro-Med, Inc; W. Warwick, RI) interfaced with a 
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stimulator (S88; Astro-Med, Inc; W. Warwick, RI) which delivered current to the sciatic 
nerve and induced muscle contraction.   
Eccentric-Based Simulated Resistive Exercise Training   
An eccentric-based SRT protocol was utilized for training (HU+ECC).  At the 
beginning of each session, the daily peak isometric torque (P0) was determined.  The 
foot was held fixed at 0° and successive stimulations were conducted at different 
voltages, with the frequency kept constant at 175 Hz (~4-6 contractions, 200ms duration, 
45s rest between contractions).  The voltage and magnitude of P0 were recorded.  This 
voltage was maintained for the eccentric contractions, and the stimulation frequency was 
varied until the torque matched P0 (i.e., 100% peak isometric torque).  This normally 
took 3-5 contractions, each at 200ms, with 45s of rest between contractions).  A rest 
period of 2 minutes was given between the isometric and eccentric contraction 
optimization protocols.  Upon completion of eccentric frequency optimization, the 
training program was initiated.  Four sets of 5 repetitions (12 and 120 seconds of rest 
inserted between contractions and sets, respectively) were completed during each 
training session, which lasted approximately 25 minutes.  Each eccentric contraction 
stimulus was 1000 ms long.  During each plantarflexor muscle lengthening contraction, 
the footplate was rotated in dorsiflexion through a 40° arc (centered at the 0° position) 
(Fig 2B).  After each contraction, the foot and pedal returned to the initial 0° resting 
position.  Plantarflexor muscles fatigued by an average of 17.8% (maximum torque 
generated during the last set vs. the first set) during a typical training session.       
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Isometric Plus Eccentric Simulated Resistive Exercise Training  
The ability of a longer duration contraction with isometric and eccentric 
components (both at 100% P0) to maintain musculoskeletal health during unloading was 
also tested (HU+ISO/ECC).  Voltage optimization of the peak isometric torque and 
frequency optimization of the eccentric torque were performed at the beginning of each 
session, as described in the previous paragraph.  The total number sets, repetitions, and 
training sessions were identical to those of the HU+ECC group.  In this case, however, 
the training protocol consisted of a 1000ms isometric contraction (175 Hz; 0°), 
immediately followed by a 1000ms eccentric contraction the same as those used for the 
eccentric contractions in experiment 1 (Fig 2C).  By the end of a typical training session, 
plantarflexor muscles fatigued by an average of 34.2% and 39.8% for isometric and 
eccentric contractions, respectively.  These reductions in torque are similar to previous 
investigations utilizing 2-second muscle stimulation contractions (95).   
  
Muscle Function Testing 
 Functional assessments of the left leg plantarflexor muscles were completed on 
days 0 and 28 on animals in the ANHU, HU+ECC, and HU+ISO/ECC groups using the 
same isokinetic dynamometer (93) used for the SRT protocols.  The anesthesia used, 
preparation of the animal, and electrodes’ placements were identical to those used during 
training.  Briefly, stimulation voltage was optimized using 0.1-ms pulses at 300 Hz to 
yield the peak isometric torque during a trial of 4-6 tetanic contractions.  Peak torque 
produced about the ankle was recorded using custom software written in TestPoint. 
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Fig. 2. Simulated resistive exercise apparatus used for muscle contractions (A) and 
sample torque/angle vs. time graphs during 28-day hindlimb unloading (B – HU+ECC; 
C – HU+ISO/ECC).  Arrows illustrate movement of the footplatre for eccentric 
contractions; footplate held steady for isometric contractions (A).  Electrodes run from 
Grass Instruments (S88) stimulator; Cambridge servomotor (Model 6900) quantitates 
torque around the ankle and determines eccentric/isometric nature of contractions.  
Dotted line on the graphs (B and C) represents change in foot-pedal and ankle angle 
during contraction; solid line represents muscle torque output.   
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Peripheral Quantitative Computed Tomography Scans 
On days -1 and 28 of the study, tomographic scans were performed in vivo at the 
proximal and mid-diaphysis of the left tibia with a Stratec XCT Research-M device 
(Norland Corp., Fort Atkinson, WI), using a voxel size of 100 μm and a scanning beam 
thickness of 500 μm.  Daily calibration of this machine was performed with a 
hydroxyapatitie standard cone phantom.  Transverse images of the left tibia were taken 
at 5.0, 5.5, and 6.0 mm from the proximal tibia plateau, as well as one slice at the 
midshaft (50% of the total tibia length).  A standardized analysis for either metaphyseal 
bone (contour mode 3, peel mode 2, outer threshold of 0.214 g/cm
3
, inner threshold of 
0.605 g/cm
3
) or diaphyseal bone (separation 1, threshold of 0.605 g/cm
3
) was applied to 
each section.   
 Values of total and cancellous volumetric bone mineral density (vBMD), total 
bone mineral content (BMC), total bone area, and marrow area were averaged across the 
3 metaphyseal slices for each outcome variable.  For each mid-diaphyseal slice, the 
outcome variables were cortical vBMD, BMC, cortical bone area, and the polar cross-
sectional moment of inertia (CSMI).  Machine precision (based on manufacturer’s data) 
is 3 mg/cm3 for cancellous vBMD and 9 mg/cm3 for cortical vBMD.  Coefficients of 
variation were  1.24, 2.13, and 1.95% for in vivo proximal tibia total vBMD, 
cancellous vBMD, and total area, respectively, as determined from repeat scans on adult 
male rats. 
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Histomorphometry Analysis 
  
 Undemineralized distal left tibia were subjected to serial dehydration and 
embedded in methylmethacrylate (Sigma-Aldrich M5, 590-9).  Serial cross-sections 
(150-200 µm) of mid-shaft cortical bone were cut starting 2.5 mm proximal to the tibial-
fibular junction with an Isomet diamond wafer low-speed saw (Buehler, Lake Bluff, IL).  
Sections were hand ground to reduce thickness (<80 µm) before mounting on glass 
slides.  The histomorphometric analyses were performed using the OsteoMeasure 
Analysis System, Version 1.3 (OsteoMetrics, Atlanta, GA).  Measures of labeled 
surfaces and interlabel widths were obtained at 100x magnification of up to 3 slides per 
animal.  Periosteal and endocortical mineral apposition rates (MAR, µm/d) were 
calculated by dividing the average interlabel width by the time between labels (7 days), 
and mineralizing surface (MS) for both periosteal and endocortical bone surfaces was 
calculated using the formula %MS/BS = {[(single labeled surface/2) + double labeled 
surface]/surface perimeter} X 100.  Bone formation rate (BFR) was calculated as (MAR 
x %MS/BS).   
 
Biomechanical Testing 
 Proximal tibiae from animals in the CC, HU, and HU+ECC groups were tested 
for changes in cancellous bone material properties using reduced platen compression 
(RPC) test as previously described (96).  Briefly, a 2-mm thick cross-section was cut 
from the proximal tibia just distal to the primary spongiosa of the metaphysis.  Each 
specimen thus consists of a central core of cancellous bone encompassed by the 
33 
 
surrounding cortical shell.  Contact radiographs were made of each specimen to 
determine the appropriate size for the loading platens such that the platens contact only 
the cancellous bone and not the cortical shell.  Quasi-static loading was applied at 2.54 
mm/min to compress the specimen until failure occurred using an Instron 1125 load 
frame (Norwood, MA).  Load and displacement were recorded digitally in real time at 
10Hz.  Load-displacement data were analyzed to determine the stiffness (slope of linear 
loading portion) and the ultimate load (maximum force during test).  Cancellous bone 
material properties (elastic modulus, EM; and ultimate stress, US) were estimated 
assuming uni-axial compression of the cancellous bone material only, that is, assuming 
an "effective" specimen with a height equal to the specimen thickness and a cross-
sectional area equivalent to that of the platen surface area.  The equations used are:  EM 
= (stiffness x specimen thickness) / platen surface area, and US = ultimate load/platen 
surface area.   
 Whole left tibiae were tested in three-point bending to assess cortical bone 
structural and material properties at the mid-diaphyseal pQCT sampling site (50% of 
total bone length).  Thawed tibia from animals in the ANHU and HU+ISO/ECC groups 
were placed lateral side down on custom-built metal pin supports having a span of 
18mm.  The loading pin was centered above the lower supports and contacted the medial 
surface at the midpoint of the specimen (mid-diaphysis).  Quasi-static loading was 
applied at 2.54 mm/min through the loading pin until fracture occurred.  Load and 
displacement were recorded at 10 Hz.  Load-displacement curves were analyzed to 
determine the structural variables of ultimate force (UF) and stiffness (S), the latter of 
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which was defined to be the slope of the elastic linear portion of the loading curve.  The 
yield point was defined to be the intersection of the load-displacement curve with a line 
having a slope 90% of the stiffness.  The corresponding load value was the yield force 
(YF).  Material properties were estimated by normalizing structural properties for the 
bone geometry using the bending cross-sectional moment of inertia (bCSMI; from 
pQCT), bone diameter (D; measured by calipers), and the support span distance 
(L=18mm).  The cross-sectional moment of inertia for bending, bCSMI, was estimated 
as half of the polar CSMI.  Standard beam theory was applied to estimate the material 
properties of elastic modulus (EM) and ultimate stress (US) as follows:  EM = (S x L
3
) / 
(48 x bCSMI x 1000); US = [UF x L x (D/2)] / (4 x bCSMI). 
 
Statistical Analyses 
All data were expressed as means ± SEM and evaluated using the statistical 
package SPSS (v.15; Chicago, Ill).  In vivo pQCT and body mass delta scores and 
muscle mass at sacrifice were first analyzed using a two-factor ANOVA to compare 
group differences between HU, ANHU, HU+ECC, and HU+ISO/ECC.  A Tukey’s post-
hoc test was used for pair-wise comparisons.  Subsequently, a one-factor ANOVA was 
used to compare individual group change scores vs. that of the comparator cage control 
(CC) group (Tukey’s post-hoc test for pairwise comparisons), and paired t-tests to 
determine (using absolute date values pre-post within group) whether that change score 
represented a significant change from Day 0.  Comparisons of mechanical properties of 
cancellous bone, cortical bone histomorphometric variables, and delta scores for muscle 
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peak torque values were tested using a one-factor ANOVA, with a Tukey’s post-hoc test 
for pairwise comparisons.  Paired t-tests were used on absolute values of muscle peak 
torque pre- and post-values to determine if the change score represented a significant 
change from Day 0.  Cortical bone mechanical properties in HU+ISO/ECC and ANHU 
animals were compared with unpaired t-tests.  For all data, statistical significance was 
accepted at p<0.05. 
 
Results 
Two animals from the HU+ECC group and one from the HU+ISO/ECC group 
died from complications due to isoflurane aministration.  No other animals suffered any 
deleterious effects of either HU or anesthesia during the study that led to their removal.   
Simulated resistance training attenuates muscle mass and strength losses during 
disuse.  HU alone resulted in no change in body mass, whereas all 3 HU groups 
receiving anesthesia did exhibit some loss in body mass (-5.5 to -7.8%) by 28 days 
(Table 1).  Simulated resistance training paradigms did not attenuate HU-induced losses 
in body mass.  Unloading resulted in significantly lower left plantarflexor muscle masses 
as compared to CC rats, and this reduction was partially attenuated by both exercise 
paradigms (Table 1).  Additionally, when normalized to body mass, total plantarflexor 
muscle mass of the trained left leg in both SRT groups was significantly higher than both 
HU and ANHU groups (p<0.05). 
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Table 1.  Effects of hindlimb unloading (HU) and high intensity muscle contractions on 
whole-body and left plantarflexor muscle masses.   
 
 
 
Values are group mean  standard error of the mean.  Those HU groups not sharing the 
same letter for each variable are significantly different from each other (p<0.05); 
comparisons with CC (by t-test): †Significantly different vs. CC (p<0.05); *p<0.05 vs. 
pre value.  
 
 
 
Eccentric (HU+ECC) and combined eccentric+isometric-based (HU+ECC/ISO) 
hindlimb muscle contractions successfully prevented any loss in P0 (Fig 3).  
Additionally, the 14 sessions of anesthesia exposure combined with 28 days of 
mechanical unloading (ANHU) resulted in a significant 10.2% reduction in peak 
isometric torque. 
 
            
  CC HU HU+ALEN HU+SRT HU+SRT/ALEN 
Body Mass (g)           
Day 0 454.58 ± 6.56 447.73 ± 15.89 438.31 ± 6.39 442.42 ± 7.78 436.36 ± 6.09 
Day 28 478.75 ± 8.50* 412.00 ± 13.35* 414.15 ± 9.58* 409.08 ± 8.28* 389.36 ± 8.04* 
Body Mass Change (g) 24.17 ± 3.08*        
(5.32%) 
35.73 ± 5.25ab†         
(-7.98%) 
(-24.15 ± 5.81a†)       
(-5.50%) 
(-33.33 ± 4.65a†)       
(-7.53%) 
(-47.00 ± 5.24b†)       
(-10.77%) %-Change 
 
 
    Ankle Plantarflexor Masses (g) 
     Gastrocnemius 2.312 ± 0.135 1.732 ± 0.035† 1.845 ± 0.057† 1.607 ± 0.058† 1.663 ± 0.044† 
Plantaris 0.513 ± 0.009 0.392 ± 0.010† 0.401 ± 0.011† 0.374 ± 0.015† 0.359 ± 0.010† 
Soleus 0.199 ± 0.006 0.088 ± 0.004a† 0.107 ± 0.007b† 0.096 ± 0.004ab† 0.101 ± 0.004b† 
Total Mass 3.025 ± 0.128 2.212 ± 0.039† 2.353 ± 0.068†  2.072 ± 0.064† 2.100 ± 0.051† 
Relative Total Mass/BW (mg/g) 6.347 ± 0.297 5.41 ± 0.165a† 5.682 ± 0.290a† 4.662 ± 0.421b† 4.922 ± 0.465ab† 
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Fig. 3.  Effects of hindlimb unloading and high intensity muscle contractions on in vivo 
measurement of peak isometric torque of the ankle plantarflexor muscles.  Values are 
change in group mean  standard error of the mean.  Those groups not sharing the same 
letter for each variable are significantly different from each other (p<0.05). 
*Significantly different for Post vs. Pre value (p<0.05).   
 
 
Simulated resistance training not only mitigates loss of bone mass but stimulates 
gain during disuse.  Hindlimb unloading resulted in reduced total BMC (-11%) and 
total bone area (-8%) at the PTM (Fig 4B-C); most of this bone loss appears to occur in 
the cancellous compartment, as cancellous vBMD declined by 14% (Fig 4D).  SRT 
during HU not only prevented the loss of total metaphyseal vBMD (Fig 4A) but resulted 
in significantly increased total vBMD (+12-13% post vs. pre values; both SRT groups) 
and total BMC (+17% post vs. pre; ISO/ECC group) at this disuse-sensitive site.  In 
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addition, both SRT paradigms led to a complete maintenance of cancellous bone during 
unloading.  HU+ECC rats experienced significantly greater reductions in marrow area as 
compared to HU rats (Fig 4E), possibly resulting from endocortical formation.   
Similar to the effects at the PTM, both SRT protocols increased bone mass at the 
midshaft tibia after 28 days (Fig 5).  Although no significant changes were noted in 
cortical vBMD with either hindlimb unloading or SRT (Fig 5A), cortical BMC increased 
by 15 and 11% in HU+ECC and HU+ISO/ECC rats, respectively, surpassing the 7% 
gain observed in CC rats (Fig 5B).   For structural and geometric properties, unloading 
resulted in a suppression of growth-related increases (Fig 5C-D; HU and ANHU 
groups), but the beneficial effect of both SRT protocols was again strongly evident.  
Bone area increased by 14 and 10% in the HU+ECC and HU+ISO/ECC groups, 
respectively (Fig 5C), and the change in polar CSMI was significantly greater in the 
HU+ECC group as compared to non-exercised unloaded animals (Fig 5D). 
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Fig. 4.  Effects of hindlimb unloading and high intensity muscle contractions on changes 
in structural and geometric properties of the proximal tibia metaphysis as taken by in 
vivo peripheral quantitative computed tomography scans.  A: Total volumetric bone 
mineral density (vBMD). B: Total bone mineral content (BMC). C: Total bone area. D: 
Cancellous volumetric bone mineral density (vBMD). E: Marrow area.  Vertical dashed 
line indicates separation of CC from the experimental groups for preliminary ANOVA.  
Those HU groups not sharing the same letter for each variable are significantly different 
from each other (p<0.05); comparisons with CC (by t-test): †Significantly different vs. 
CC (p<0.05); 
*
p<0.05 vs. pre value.  
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Fig. 5.  Effects of hindlimb unloading and high intensity muscle contractions on changes 
in structural and geometric properties of the tibial mid-diaphysis as taken by in vivo 
peripheral quantitative computed tomography scans.  A: Cortical volumetric bone 
mineral density (vBMD). B: Cortical bone mineral content (BMC). C: Cortical bone 
area. D: Polar cross-sectional moment of inertia (CSMI).  Vertical dashed line indicates 
separation of CC from the experimental groups for preliminary ANOVA.  Those HU 
groups not sharing the same letter for each variable are significantly different from each 
other (p<0.05); comparisons with CC (by t-test): †Significantly different vs. CC 
(p<0.05); 
*
p<0.05 vs. pre value.   
 
 
 
 
 
 
 
CC HU ANHU HU+ECC HU+ISO/ECC

C
o
rt
ic
a
l 
B
M
C
 (
m
g
)
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
* a 
* a 
b 
b 
+7% +3% 
0% 
+15% +11% 
† 
† 
† 
† 
 
CC HU ANHU HU+ECC HU+ISO/ECC

C
o
rt
ic
a
l 
B
o
n
e
 A
re
a
 (
m
m
2
)
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
* a 
* b 
+6% +1% 
-1% 
+14% +10% 
† 
c †  
c †  
 
CC HU ANHU HU+ECC HU+ISO/ECC

C
o
rt
ic
a
l 
v
B
M
D
 (
m
g
/c
m
3
)
0
5
10
15
20
25
a 
a 
a 
a 
+1% +1% +1% +1% +1% 
 
CC HU ANHU HU+ECC HU+ISO/ECC

C
S
M
I 
(m
m
4
)
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
a b 
* a 
b 
b 
+17% +5% +3% +24% +13% 
C. D.
A. B.
41 
 
 
 
Fig. 6.  Effects of hindlimb unloading and high intensity eccentric muscle contractions 
on periosteal and endocortical surface dynamic histomorphometry analyses measured at 
the tibia diaphysis.  A: Mineralizing Surface (%MS/BS). B: Mineral Apposition Rate 
(MAR). C: Bone Formation Rate (BFR).  Those groups not sharing the same letter for 
respective surface measures are significantly different from each other (p<0.001). 
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Simulated resistance exercise increases bone formation on cortical surfaces.  
Hindlimb unloading virtually abolished periosteal %MS/BS, MAR, and BFR (Fig 6 A-
C).  These results are all endpoint values (day 28 only), and the differences between the 
HU and CC groups are -99%, -38%, and -99% for %MS/BS, MAR, and BFR, 
respectively.  SRT effectively abolished the deficit in %MS/BS observed in hindlimb 
unloaded animals and stimulated a dramatic increase in periosteal MAR and BFR , with 
values 5- and 6-fold greater, respectively, than those observed in CC rats.  There was 
little evidence of bone formation activity on endocortical surfaces in ambulatory CC and 
HU rats, whereas HU animals subjected to SRT exhibited much higher values for 
%MS/BS, MAR and BFR.  Few fluorochrome labels were present on either surface in 
HU rats (Fig 7B). 
 
 
 
Fig. 7.  Visual depiction (100x) of calcein labeling on the periosteal surface of cortical 
bone at the tibia diaphysis.  A: CC B: HU C: HU+ECC.  Note the extensive flurochrome 
labeling (arrows) in CC and HU+ECC and large interlabel width (HU+ECC). 
 
Muscle contractions improve cancellous but not cortical bone material properties.  
Reduced platen compression (RPC) testing was used determine the effects of HU and the 
 
A.
 
B. C.
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eccentric-based SRT protocol on material properties of cancellous bone.  Eccentric-
based exercise during HU resulted in significantly higher estimated values for both the 
elastic modulus and ultimate stress values (Table 2).  The elastic modulus of the 
HU+ECC animals was 3.1 and 4.6-fold higher than values in CC and HU rats, 
respectively.  The ultimate stress of the HU+ECC animals was 2.6 times higher than in 
CC rats and 4.6 times higher than in HU animals.  Although HU rats exhibited lower 
elastic modulus and ultimate stress values (by 33% and 4%, respectively), as compared 
to ambulatory aging controls, these differences were not statistically significant.   
The effects of eccentric-based muscle contractions on changes in mechanical 
properties of left tibia cortical bone with unloading yielded no significant effects of a 
combined isometric and eccentric muscle stimulation protocol during 28-day hindlimb 
unloading (data not shown).  Extrinsic (maximal force, yield force, and stiffness) and  
intrinsic (elastic modulus, ultimate stress, and yield stress) mechanical properties of 
cortical bone were not significantly different in ANHU compared to HU+ISO/ECC 
groups. 
 
 
Table 2.  Effects of hindlimb unloading and high intensity muscle contractions on 
mechanical properties of cancellous bone at the proximal tibia metaphysis.     
 
 
 
Values are group mean  standard error of the mean.  Those HU groups not sharing the 
same letter for each variable are significantly different from each other (p<0.05); group 
comparisons made with ANOVA. 
 
CC HU HU+ECC
Elastic Modulus (MPa) 21.0 ± 7.7
b
14.1 ± 3.4
b
65.5 ± 19.2
a
Ultimate Stress (MPa) 0.9 ± 0.2
b
0.5 ± 0.1
b
2.3 ± 0.5
a
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Discussion 
 Our main objective was to determine if high intensity simulated resistance 
training during hindlimb unloading would effectively mitigate disuse associated losses in 
musculoskeletal mass and strength.  We hypothesized that the in vivo exercise 
paradigms tested would lessen any HU-associated losses in both tibial bone and 
plantarflexor muscles and that doubling the contraction time would further increase this 
response.   
Most significantly, our data demonstrate that, if an isometric component is added 
to eccentric muscle contractions, bone loss is not only attenuated but an absolute 
increase in total and cancellous vBMD at the disuse-sensitive proximal tibia metaphysis 
results.  Additionally, we demonstrate large gains in mid-shaft cortical bone area and 
BMC with SRT, both of which were suppressed in HU animals (Fig 5B-C).  The 
increased bone mass at the tibial mid-diaphysis resulted from strikingly higher cortical 
bone formation on the periosteal surface and activation of endocortical formation in 
eccentrically trained animals that was virtually absent in ambulatory controls and 
hindlimb unloaded rats.  The HU+ECC and HU+ECC/ISO simulated resistive exercise 
paradigms successfully preserved in vivo muscle isometric strength (post vs. pre), 
whereas unloaded animals experienced a 10% reduction in strength.  The SRT protocols 
also mitigated unloading-associated losses in muscle mass.  Thus, our data suggest that a 
low volume of high intensity muscle contractions, with isometric and eccentric 
components, can effectively maintain musculoskeletal mass and strength during 28 days 
of hindlimb unloading.   
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 Lower leg disuse in rodents leads to significant hindlimb muscle atrophy in as 
little as 4 days (97,98).  Previous studies have shown that maximal voluntary isometric 
exercise during HU effectively maintains soleus mass and strength (99), but muscle 
stimulation is unable to diminish reductions in medial gastrocnemius mass or protein 
content (100).  Additionally, more physiological contractions (combined isometric + 
concentric + eccentric) during unloading were able to maintain muscle mass and 
myofibril protein content (95).  None of these previous studies tested changes in 
unloaded muscle beyond 14 days of unloading, and few examine outcomes for a 
functional muscle group (as opposed to the disuse-sensitive soleus muscle).  Our 
investigation sought to prevent unloading-induced changes in plantarflexor muscle mass 
and strength over a much longer duration and provides the first report of longitudinal in 
vivo measures of muscle strength (in rodents).  Both resistive exercise protocols used in 
the present study mitigated losses in gastrocnemius and soleus mass, as well as total and 
relative plantarflexor masses (Table 1).  Importantly, isometric strength of these muscles 
was maintained at pre-HU levels, whereas hindlimb unloading without intervention 
significantly reduced muscle strength by more than 10% (Fig 3).   
Previous investigations have sought to define the osteogenic effect of mechanical 
loading during periods of disuse.  Rubin et al. (55),employing low-magnitude, high-
frequency loads, found that 10min/d of loading was effective at maintaining metaphyseal 
bone volume (BV/TV) and did attenuate losses in bone formation at the proximal tibia.  
More recent studies have utilized electrical stimulation as a countermeasure to disuse-
induced bone loss.  Transcutaneous stimulation of the thigh, producing peak strains of 
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~200, did not effectively prevent disuse osteopenia in hindlimb unloaded rodents, but 
did reduce tibial bone loss (56).  Lam and Qin (58) recently demonstrated the beneficial 
effects of high frequency electrical stimulation of the leg musculature on bone during 
disuse.  Although this treatment did effectively mitigate losses of cancellous bone 
volume in the unloaded distal femur, there was no demonstrable effect on bone 
formation.  Their model stimulates muscle contraction in an unrestrained leg, generating 
relatively small muscle forces and presumably low strain levels on the associated bone.  
By contrast, our simulated resistive exercise protocols provide a more physiological 
loading of muscle with quantifiable torque production at the restrained ankle.  The 
loading stimulus can be manipulated to any desired intensity, even exceeding 100% peak 
isometric torque during eccentric contractions, and can generate concentric, eccentric or 
isometric contractions.   
Significant increases in periosteal bone formation rate in the HU+ECC group 
(Fig 6C) contributed to absolute gains in cortical bone mass as compared to controls, 
more than reversing the losses observed in HU animals (Fig 5).  Periosteal bone 
formation at mid-shaft tibia was approximately 7-fold higher in HU+ECC rats than in 
CC animals, which was largely attributable to a 5-fold higher mineral apposition rate.   
  Both of our resistive exercise paradigms effectively mitigated bone loss in 
unloaded hindlimbs and actually led to gains in cortical bone mass (Fig 5), while 
maintaining disuse-sensitive cancellous bone at the proximal tibia (Fig 4D).  Combined 
isometric and eccentric contractions resulted in a 5% increase in cancellous vBMD over 
28 days, whereas untreated HU animals exhibited 14-15% reductions.   Those animals 
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treated with only eccentric-based contractions effectively maintained cancellous vBMD 
during the period of disuse.  Importantly, this cancellous bone compartment exhibited 
dramatic increases in material properties, with ultimate stress and elastic modulus values 
approximately 4-fold higher in HU+ECC vs. unloaded animals (Table 2).  Discrepancies 
in effects on cancellous vBMD versus changes in mechanical properties are not 
uncommon because bone density, volume, and mass can sometimes be imperfect 
measures of bone condition, particularly for cancellous bone.  Other prominent factors 
contributing to mechanical performance include the cancellous architecture and the 
quality of the solid bone tissue, with the latter encompassing mineral and organic matrix 
compositional and ultrastructural features.  Changes in these bone quality-related 
variables sometimes gives rise to a disassociation between density or volume and bone 
strength.  An example of this effect was reported by Allen et al. (101) describing 
changes in mechanical properties of cancellous bone with raloxifene treatment.  The 
treated and control groups had essentially the same BV/TV, yet material properties were 
substantially higher in the treated group (ultimate stress 130% higher, elastic modulus 
89% higher).  Accordingly, our results suggest that the exercise protocol may very well 
have induced positive adaptations in the organic matrix of the cancellous bone and/or 
enhancements in cancellous bone microarchitecture.  To our knowledge, these are the 
first exercise paradigms utilized during disuse that effectively produce absolute gains in 
cancellous bone mass and/or in cancellous bone material properties.    
The simulated resistance training protocols tested were successful in achieving, 
at minimum, maintenance of cortical and cancellous bone mass and attenuation of 
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muscle mass and strength losses associated with hindlimb unloading.  However, the 
degree to which each regimen achieved these was not equal.  Both exercise regimens 
significantly increased cortical BMC and bone area, yet only in the HU+ECC animals 
did the gain in area result in a significant increase in polar cross-sectional moment of 
inertia.  When an isometric component was added to the eccentric contraction, greater 
benefits to disuse-sensitive cancellous bone occurred.  Although both SRT groups 
experienced equivalent increases in total vBMD at the proximal tibia, only the 
HU+ISO/ECC protocol significantly increased total BMC and mitigated reductions in 
bone area.  In sum, these data suggest a bone compartment-specific response to the 
different contraction paradigms.  Training using eccentric-only contractions had the 
greater effect on the mid-diaphysis cortical bone shell, whereas a combined 
eccentric+isometric training paradigm resulted in greater effects in cancellous bone, as 
measured by in vivo pQCT scans.  Additionally, both exercise protocols were successful 
in preventing hindlimb unloading-associated losses in muscle strength and mitigating 
loss of muscle mass.    
The effectiveness of our simulated resistance training protocols in maintaining 
plantarflexor muscle strength and increasing bone mass during disuse may offer some 
important insight regarding the efficacy of exercise interventions for human subjects 
exposed to prolonged bed rest.  Only a few long-term bed rest investigations have 
successfully mitigated bone loss with exercise paradigms.  Combined supine flywheel 
resistive and treadmill exercise during 90-day bed rest in young men attenuates 
reductions in trochanter and hip BMD (53).  Treadmill exercise combined with lower-
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body negative pressure effectively maintains total hip and femoral shaft BMD (87) and 
lumbar spine muscle strength (86).  Vigorous resistance training during 17-week bed rest 
increased lumbar spine and diminished reductions in total hip BMD, as well as 
attenuated losses of leg muscle masses and strength compared with bed rest controls 
(54).  These data mirror the findings of our rodent protocol, with the exception that our 
exercised animals experienced absolute gains in bone mass and not merely mitigation of 
losses.  Our present study, using invasive measures feasible only in an animal model, 
illustrates the efficacy of a high intensity resistive exercise intervention in maintaining 
musculoskeletal mass and strength during long duration disuse.  Our results suggest that, 
should newer exercise equipment now being installed in the ISS more effectively 
provide for higher intensity resistance training, the currently intractable problem of bone 
loss during prolonged missions may be partially solved. 
There were several limitations to the current investigation.  This study utilized 
two separate cohorts of animals, which were not equally and randomly assigned to all 
representative groups.  To most fairly represent the data across these two cohorts, we 
normalized all longitudinal data (in vivo pQCT and muscle strength) by expressing them 
as change values.  Additionally, lacking detailed histomorphometric measures at the 
proximal tibia metaphysis, we cannot verify tissue-level mechanisms (increased 
formation and/or decreased resorption) for the gains in cancellous vBMD and in material 
properties in this bone compartment observed with our exercise interventions.     
In summary, our data demonstrate that high intensity simulated resistance 
training during unloading leads to absolute increases in disuse-sensitive cancellous bone 
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mass and material properties, while maintaining muscle strength.  The exercise 
paradigms used in this investigation during disuse also stimulated increases in midshaft 
BMC and bone area, which gains were found to be attributed to dramatic increases in 
periosteal bone formation.  These data provide the first direct evidence that high-
intensity, eccentric-based resistive exercise, begun early during the period of unloading, 
can prevent the loss of bone mass and muscle strength routinely observed during a 
period of disuse or exposure to microgravity.   
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CHAPTER IV 
CANCELLOUS BONE RESPONSE TO SIMULATED RESISTANCE TRAINING IS 
BLUNTED BY CONCOMITANT ALENDRONATE TREATMENT DURING DISUSE 
 
Introduction 
Significant bone loss remains a persistent problem for humans exposed to 
microgravity, with little evidence of consistent recovery upon return to Earth.   Recently, 
Lang and colleagues (15) have demonstrated significant reductions in bone mineral 
density (BMD) and geometry in astronauts aboard the International Space Station (4-6 
month missions), which losses result in increased estimated fracture risk up to 1 year 
after returning to Earth (16,17).  Additionally, lack of recovery of BMD in ISS and MIR 
crew members has been documented 6 months post-flight (14), with indications that it 
may not be fully restored for 3 years (18).  The ability of current resistance exercise 
countermeasures installed on ISS (iRED, interim resistance exercise device; and aRED 
advanced resistance exercise device) to mitigate reductions in lower leg bone mass and 
strength has yet to be validated (85).  Furthermore, if these exercise devices are unable to 
provide sufficient mechanical loading and a crew member fracture did occur in 
microgravity, it would be debilitating and may compromise mission objectives, 
particularly if crews are to be working on the lunar or Martian surface as currently 
planned in the National Aeronautics and Space Administration’s (NASA) “Vision for 
Space Exploration” (102). 
52 
 
 
The rodent hindlimb unloading (HU) model is a well-established ground-based 
model for investigating disuse effects on bone and muscle (20).  Hindlimb unloading 
results in significant reductions in disuse-sensitive cancellous bone mass, architecture and 
material properties, due to early increases in bone resorption followed by prolonged 
depressions in bone formation rate (BFR) (21,103-105).  These reductions in metaphyseal 
bone mass are associated with increased osteocyte and osteoblast apoptosis.  Recent data 
demonstrate a striking 66% increase in apoptotic osteocytes at the proximal tibia with 14 
days of HU and increased cancellous and cortical osteocyte apoptosis in unweighted 
tibiae by day 3 of HU (106,107).  Reducing osteocyte apoptosis within the metaphyseal 
region of hindlimb bone during unloading may be crucial to preserving cancellous bone 
mass and reducing bone resorption.     
Previously, our lab has demonstrated the significant positive effects of high 
intensity muscle contractions, produced during rodent simulated resistance training 
(SRT), on unweighted tibia bone.  SRT, completed every other day, results in absolute 
increases in disuse-sensitive cancellous bone mass and material properties, while 
maintaining muscle strength (105).  Furthermore, significant gains in mid-diaphyseal 
tibia cortical bone mineral density were associated with a 5-fold greater periosteal bone 
formation rate (BFR) as compared to control animals.  However, we have not yet 
identified the cellular mechanisms by which our SRT protocol inhibits unloading-induced 
reductions in cancellous bone mineral density (BMD). 
The inability of current exercise hardware to prevent microgravity-induced losses 
in skeletal tissue may be inconsequential if the use of pharmacological agents in-flight 
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proves to be a more effective and less time-intensive countermeasure.  Alendronate 
(ALEN), an anti-resorptive agent, has been approved by NASA for in-flight experiments 
(108).  Alendronate is a nitrogen-containing bisphosphonate that inhibits bone resorption 
by adsorbing to bone mineral; it interferes with osteoclast activity by inhibiting enzymes 
of the mevalonate pathway, and ultimately contributes to osteoclast apoptosis (109).  
Additionally, ALEN is currently in use for treatment of various disorders characterized 
by increased osteoclast-mediated bone resorption, and is a proven agent in minimizing 
bone loss due to estrogen deficiency and disuse in rats (65,66,110,111).  Combining anti-
resorptive therapy with the muscle-anabolic effects of resistance exercise might prove to 
be an effective approach for protecting both bone and skeletal muscle during bed rest and 
spaceflight. 
The aim of this current investigation was to determine whether combining the 
anabolic effects of SRT with the anti-resorptive effects of ALEN during 28 days of HU 
positively impacts cancellous bone.  Furthermore, we sought to define the effects of our 
SRT protocol and ALEN on the prevalence of cancellous osteocyte apoptosis.  We 
hypothesized that administering ALEN in rats also subjected to SRT during HU will 
better prevent or ameliorate deleterious changes in cancellous bone than will ALEN or 
SRT administration alone and that this effect may be due to both treatments’ ability to 
mitigate disuse associated increases in prevalence of apoptotic osteocytes. 
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Materials and Methods 
Animals and Experimental Design 
Sixty male Sprague-Dawley rats were obtained from Harlan (Houston, TX) at 6 
months of age and allowed to acclimate to their surroundings for 14 days prior to 
initiation of the study.  All animals were singly housed in a temperature-controlled (23 ± 
2ºC) room with a 12-hour light-dark cycle in an American Association for Accreditation 
of Laboratory Animal Care-accredited animal care facility and were provided standard 
rodent chow (Harlan Teklad 8604) and water ad-libitum.  Animal care and all 
experimental procedures described in this investigation were conducted in accordance 
with the Texas A&M University Laboratory Animal Care Committee rules. 
Five experimental groups were studied: (1) cage control (CC, n=12), (2) hindlimb 
unloaded (HU, n=12), (3) HU animals administered 0.01 mg/kg alendronate via 
subcutaneous injection 3 times/week (HU+ALEN, n=12), (4) HU subjected to simulated 
resistance training one time/3 days (HU+SRT, n=12), and (5) HU rats subjected to both 
ALEN and SRT (HU+SRT/ALEN, n=12).  HU+SRT and HU+ALEN/SRT animals 
underwent 9 sessions of simulated resistive exercise conducted once every three days 
during the 28 day protocol.  The HU group was similarly unloaded for 28 days and 
exposed to the same duration (25 min) of isoflurane anesthesia (Minrad Inc., Bethlehem, 
PA) as trained HU rats, whereas the CC animals were allowed normal ambulatory cage 
activity.   
Calcein injections (25 mg/kg body mass) were given subcutaneously 9 and 2 days 
prior to sacrifice to label mineralizing bone for histomorphometric analysis.  HU animals 
55 
 
 
were anesthetized before removal from tail suspension at the end of the study to prevent 
any weight bearing by the hindlimbs.  At necropsy, left soleus, plantaris, and 
gastrocnemius muscles were excised and wet weights were recorded.  Additionally, 
proximal left tibiae were removed, cleaned of soft tissue, and stored in 70% ethanol at 
4°C for cancellous histomorphometry of the proximal tibia metaphysis.  Distal left 
femora were decalcified and stored at 4°C for paraffin embedding. 
 
Hindlimb Unloading 
Hindlimb unloading was achieved by tail suspension as previously described 
(105).  Briefly, while the rat was under anesthesia, the tail was cleaned and dried 
thoroughly.  A thin layer of adhesive (Amazing Goop, Eclectic Products, LA) was 
applied to the proximal half of the tail along the medial and lateral sides.  A standard 
porous tape (Kendall, Mansfield, MA) harness was pressed firmly to the glue and 
allowed to dry (~30 min).  A paper clip was used to attach the animal’s tail harness to a 
swivel apparatus on the wire spanning the top of an 18” x 18” x 18” cage.  The height of 
the animal’s hindquarters was adjusted to prevent any contact of the hindlimbs with the 
cage floor, resulting in approximately a 30° head-down tilt.  The forelimbs of the animal 
maintained contact with the cage bottom, allowing the rat full access to the entire cage.     
 
Simulated Resistance Training (SRT) Paradigm 
 Simulated resistance training was completed as previously mentioned (105).  
Briefly, left plantarflexor muscles from animals in the HU+SRT group were trained once 
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every 3 days during 28-day HU using a custom-made rodent isokinetic dynamometer.  
Animals were anesthetized with isoflurane gas (~2.5%) mixed with oxygen while 
remaining suspended, to prevent any weight bearing of the hindlimbs.  Once 
unconscious, the lateral side of the rat’s left leg was shaved and aseptically prepared.  
Each rat was then placed in right lateral recumbency on a platform, the left foot was 
secured onto the foot pedal, and the left knee was clamped so that the lower leg was 
perpendicular to the foot and the femur and tibia were at right angles to each other.  This 
was referred to as the resting, 0° position.  For isometric contractions, the foot pedal was 
held fixed in this position.  For all contractions, the footplate was rotated in 
synchronization with muscle stimulation by a Cambridge Technology servomotor system 
(Model 6900) interfaced with a 80486 66-MHz PC using custom software written in 
TestPoint (v.4.0; Capital Equipment Corp., Billerica, MA).  In either case, the torque 
generated around the footplate pivot (at the rat’s ankle joint) was measured through the 
servomotor.  Plantarflexor muscle stimulation was performed with fine wire electrodes 
consisting of insulated chromium nickel wire (Stablohm 800B, H-ML Size 003, 
California Fine Wire Co.), inserted intramuscularly straddling the sciatic nerve in the 
proximal thigh region.  The stimulation
 
wires were then attached to the output poles of a 
Grass Instruments stimulus
 
isolation unit (Model SIU5; Astro-Med, Inc; W. Warwick, 
RI) interfaced with a stimulator (S88; Astro-Med, Inc; W. Warwick, RI) which delivered 
current to the sciatic nerve and induced muscle contraction.   
Voltage optimization of the peak isometric torque and frequency optimization of 
the eccentric torque were performed at the beginning of each session, as described 
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previously (105).  The eccentric phase of the muscle contraction was titrated to equal 
~75% of each animal’s daily peak isometric torque.  The HU+SRT and HU+SRT/ALEN 
animals completed a combined isometric+eccentric simulated resistance training (SRT) 
exercise paradigm, consisting of 4 sets of 5 repetitions, once every 3 days during HU 
(n=9 total exercise sessions).  The training paradigm consisted of a 1000ms isometric 
contraction (175 Hz; 0°), immediately followed by a 1000ms eccentric contraction (75% 
of the peak isometric contraction). 
  
Bisphosphonate Treatment 
 Animals in the HU+ALEN, and HU+SRT/ALEN groups were administered 10 
g/kg alendronate (Merck and Co.; Rathway, New Jersey) via subcutaneous injection 
3x/week for the duration of the 28-day study.  The ALEN dose of 10 g/kg was the 
lowest dose found to effectively mitigate reductions in cancellous vBMD at the proximal 
tibia during 28-day HU in a small pilot study (unpublished data) and is similar to the 15 
g/kg ALEN (2x/week) shown to maintain femur and lumbar spine bone mass and 
strength in ovariectomized (OVX) rodents (112).  Furthermore, this dose of ALEN is 
lower than the dose used in previously published clinical studies in OVX rats 
demonstrating pronounced increases in bone mass and strength (113).  Rats in the CC, 
HU, and HU+SRT groups were administered an equal volume of vehicle (phosphate-
buffered saline).   
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Peripheral Quantitative Computed Tomography Scans 
On days -1 and 28 of the study, tomographic scans were performed in vivo at the 
proximal metaphysis of the left tibia with a Stratec XCT Research-M device (Norland 
Corp., Fort Atkinson, WI), using a voxel size of 100 μm and a scanning beam thickness 
of 500 μm.  Daily calibration of this machine was performed with a hydroxyapatite 
standard cone phantom.  Transverse images of the left tibia were taken at 5.0, 5.5, and 6.0 
mm from the proximal tibia plateau.  A standardized analysis for metaphyseal bone 
(contour mode 3, peel mode 2, outer threshold of 0.214 g/cm
3
, inner threshold of 0.605 
g/cm
3
) was applied to each section. 
Values of total volumetric bone mineral density (vBMD), total bone mineral 
content (BMC), total bone area, and cancellous vBMD were averaged across the 3 slices 
at the proximal tibia to yield a mean value.  Machine precision (based on manufacturer’s 
data) is 3 mg/cm3 for cancellous vBMD.  Coefficients of variation were  0.6, 1.6, 1.9, 
and 2.13% for in vivo proximal tibia total vBMD, total BMC, total area, and cancellous 
vBMD respectively, as determined from 3 repeat scans on each of 6 adult male rats.   
 
Histomorphometry Analysis 
 Undemineralized proximal left tibia were subjected to serial dehydration and 
embedded in methylmethacrylate (Aldrich M5, 590-9).  Serial frontal sections were cut 8 
μm thick and left unstained for fluorochrome label measurements.  Additionally, 4 μm 
thick sections treated with von Kossa staining were used for measurement of cancellous 
bone volume normalized to tissue volume (%BV/TV),  and osteoid (Os/BS), osteoblast 
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(ObS/BS), and osteoclast (OcS/BS) surfaces as a percent of total cancellous surface.  
Adipocyte density was calculated as number of adipocytes (Ad.N) divided by the marrow 
area (Ma.Ar) of the region of measurement.  The histomorphometric analyses were 
performed by using the OsteoMeasure Analysis System, Version 1.3 (OsteoMetrics, 
Atlanta, GA).  A defined region of interest was established ~1 mm from the growth plate 
and within the endocortical edges encompassing 8-9 mm
2 
at x40 magnification.  Total 
bone surface (BS), single labeled surface (SLS), double-labeled surface (DLS), interlabel 
distances, bone volume, and osteoid/osteoclast/osteoblast surfaces were measured at x200 
magnification.  Mineral apposition rate (MAR, μm/day) was calculated by dividing the 
average interlabel width by the time between labels (7 days), and mineralizing surface 
(MS) for cancellous bone surfaces (BS) was calculated by using the formula %MS/BS = 
{[(SLS/2) + DLS]/surface perimeter} X 100.  Bone formation rate (BFR) was calculated 
as (MAR x MS/BS).  All nomenclature for cancellous histomorphometry follows 
standard usage (114). 
 
Osteocyte Apoptosis 
 Distal left femora were fixed in 4% phosphate-buffered formalin for 48 hours at 
4°C and then decalcified in 10% EDTA and 4% phosphate-buffered formalin for 14 days.  
Following decalcification, the distal left femora were embedded in paraffin and serial 
frontal sections were cut 10 μm thick and mounted on slides.  Apoptosis of osteocytes 
was detected by in situ terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) using the DNA fragmentation TdT enzyme and fluorescein-dUTP label (Roche 
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Diagnostics Corp., Indianapolis, IN) in distal femoral sections counterstained with 
hematoxylin QS (Vector Laboratories; Burlingame, CA).  A defined region of interest 
was established ~1 mm from the growth plate and within the endocortical edges 
encompassing 8-9 mm
2 
at x40 magnification.  Quantification of osteocytes residing in 
trabeculae within the region of interest was performed by using the OsteoMeasure 
Analysis System, Version 1.3 (OsteoMetrics, Atlanta, GA).  The total number of 
osteocytes (N.Ot) within the region was first counted (under normal light), followed by 
identification of TUNEL+ osteocytes using ultraviolet light at 200x magnification.  The 
percentage of apoptotic osteocytes was calculated as (N.Ot /TUNEL+ Ot) x 100.   
 
Statistical Analyses 
All data were expressed as means ± SEM and evaluated using the statistical 
package SPSS (v.15; Chicago, Ill).  In vivo pQCT, body mass delta scores, muscle mass 
at sacrifice, histomorphometry, and apoptosis assays were first analyzed using a two-
factor ANOVA (exercise and alendronate) to compare group differences between HU 
groups (HU, HU+ALEN, HU+SRT, and HU+SRT/ALEN).  A Tukey’s post-hoc test was 
used for pair-wise comparisons.  Subsequently, a one-factor ANOVA was used to 
compare individual group change scores vs. that of the comparator cage control (CC) 
group (Tukey’s post-hoc test for pairwise comparisons), and paired t-tests to determine 
(using absolute date values pre-post within group) whether that change score represented 
a significant change from Day 0 (pQCT and body mass data only).  For all data, statistical 
significance was accepted at p<0.05. 
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Results 
Simulated resistance training does not prevent disuse-associated reductions in total 
body or ankle plantarflexor muscle masses.  Hindlimb unloading significantly reduced 
total body mass (-8%), which was not attenuated by ALEN (-5.5%), SRT (-7.5%), or the 
combination of both ALEN and SRT (-11%) during 28-day HU (Table 3).  Unloading 
resulted in lower gastrocnemius, plantaris, and soleus muscle masses as compared to 
ambulatory controls (24-56%).  Reduced left ankle plantarflexor muscle masses were not 
affected by SRT alone, although ALEN and SRT/ALEN mitigated the decrease in soleus 
mass.  Additionally, when normalized to body mass, SRT did not prevent reduced total 
plantarflexor muscle mass of the trained left leg (Table 3).   
 
High intensity muscle contractions, performed during unloading, inhibit reductions 
in cancellous bone mass.  Hindlimb unloading significantly reduced PTM total vBMD (-
5%), total BMC (-8%), and total bone area (-3%).  ALEN prevented HU-associated 
losses in total vBMD, but not the reductions in total BMC and bone area (Fig 8A-C).  
SRT and SRT/ALEN prevented HU-associated reductions in these parameters, resulting 
in significant increases in PTM total vBMD (7%) and total BMC (8-10%).  Cancellous 
vBMD, reduced 8% by HU-alone, was maintained with ALEN treatment (Fig 8D).  
Simulated resistance training not only inhibited disuse-associated reductions in 
cancellous vBMD, but resulted in absolute gains.  
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Table 3.  Effects of hindlimb unloading (HU) with or without alendronate (ALEN) 
treatment and/or simulated resistance training (SRT) on body mass and left ankle 
plantarflexor muscle masses.   
 
 
 
Values are group mean  standard error of the mean.  Those HU groups not sharing the 
same letter for each variable are significantly different from each other (p<0.05); 
comparisons with CC: †Significantly different vs. CC (p<0.05); *p<0.05 vs. pre value.  
Group means with no labels are not significantly different.   
            
  CC HU HU+ALEN HU+SRT HU+SRT/ALEN 
Body Mass (g)           
Day 0 454.58 ± 6.56 447.73 ± 15.89 438.31 ± 6.39 442.42 ± 7.78 436.36 ± 6.09 
Day 28 478.75 ± 8.50* 412.00 ± 13.35* 414.15 ± 9.58* 409.08 ± 8.28* 389.36 ± 8.04* 
Body Mass Change (g) 24.17 ± 3.08*        
(5.32%) 
35.73 ± 5.25ab†         
(-7.98%) 
(-24.15 ± 5.81a†)       
(-5.50%) 
(-33.33 ± 4.65a†)       
(-7.53%) 
(-47.00 ± 5.24b†)       
(-10.77%) %-Change 
 
 
    Ankle Plantarflexor Masses (g) 
     Gastrocnemius 2.312 ± 0.135 1.732 ± 0.035† 1.845 ± 0.057† 1.607 ± 0.058† 1.663 ± 0.044† 
Plantaris 0.513 ± 0.009 0.392 ± 0.010† 0.401 ± 0.011† 0.374 ± 0.015† 0.359 ± 0.010† 
Soleus 0.199 ± 0.006 0.088 ± 0.004a† 0.107 ± 0.007b† 0.096 ± 0.004ab† 0.101 ± 0.004b† 
Total Mass 3.025 ± 0.128 2.212 ± 0.039† 2.353 ± 0.068†  2.072 ± 0.064† 2.100 ± 0.051† 
Relative Total Mass/BW (mg/g) 6.347 ± 0.297 5.41 ± 0.165a† 5.682 ± 0.290a† 4.662 ± 0.421b† 4.922 ± 0.465ab† 
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Fig. 8.  Effects of hindlimb unloading (HU) with or without alendronate (ALEN) 
treatment and/or simulated resistance training (SRT) on changes in structural and 
geometric properties of the proximal tibia metaphysis as taken by in vivo peripheral 
quantitative computed tomography scans.  A: Total volumetric bone mineral density 
(vBMD). B: Total bone mineral content (BMC). C: Total bone area. D: Cancellous 
volumetric bone mineral density (vBMD).  Vertical dashed line indicates separation of 
CC from the experimental groups for preliminary ANOVA.  Those HU groups not 
sharing the same letter for each variable are significantly different from each other 
(p<0.05); comparisons with CC: †Significantly different vs. CC (p<0.05); *p<0.05 vs. 
pre value. 
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Fig. 9.  Effects of hindlimb unloading (HU) with or without alendronate (ALEN) 
treatment and/or simulated resistance training (SRT) on cancellous bone dynamic 
histomorphometry analyses measured at the proximal tibia metaphysis.  A: Mineralizing 
Surface (%MS/BS). B: Mineral Apposition Rate (MAR). C: Bone Formation Rate 
(BFR). D: Visual depiction (100x magnification) of calcein labeling of cancellous bone.  
Note the extensive fluorochrome labeling (arrows) in CC, HU+SRT, and 
HU+SRT/ALEN and large interlabel width (HU+SRT).  Vertical dashed line indicates 
separation of CC from the experimental groups for preliminary ANOVA.  Those HU 
groups not sharing the same letter for each variable are significantly different from each 
other (p<0.05); comparisons with CC: †Significantly different vs. CC (p<0.05). 
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Alendronate reduces the cancellous bone formation response to simulated 
resistance training during disuse.  Hindlimb unloading produced significantly lower 
PTM cancellous bone mineralizing surface (-60%) and mineral apposition rate (-50%), 
resulting in 81% lower bone formation as compared to ambulatory controls (Figure 9 A-
C).  ALEN administration had no effect on HU-induced reductions in cancellous bone 
formation.  SRT, undertaken during unloading, not only inhibited deficits in cancellous 
bone formation, but led to significantly greater %MS/BS (90%), MAR (25%), and BFR 
(2-fold increase) vs. CC.  When SRT was completed in combination with ALEN, 
%MS/BS and BFR were 63-70% lower than HU+SRT.  Few fluorochrome labels were 
present on cancellous bone surface of HU and HU+ALEN rodents (Fig 9D). 
 
Simulated resistance training improves metaphyseal bone microarchitecture and 
reduces adipocyte density.  HU did not significantly affect cancellous bone 
microarchitecture at the proximal tibia as compared to controls (Fig 10).  However, 
ALEN treatment during unloading resulted in reduced BV/TV and Tb.Th (9-12%) vs. 
CC (Fig 10 A-B).  Greater cancellous bone formation resulted in enhanced proximal 
tibia microarchitecture in HU+SRT and HU+SRT/ALEN groups.  BV/TV (+15%) and 
Tb.Th (+32%) were significantly greater in both SRT groups as compared to HU group.  
Furthermore, ALEN+SRT during HU produced smaller Tb.Sp (-17%) and greater Tb.N 
(+14%) as compared to HU (Fig 10 C-D). 
Hindlimb unloading resulted in significantly lower OS/BS (-40%) and Oc.S/BS 
(-45%), in addition to a 2-fold greater adipocyte density as compared to ambulatory  
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Fig. 10.  Effects of hindlimb unloading (HU) with or without alendronate (ALEN) 
treatment and/or simulated resistance training (SRT) on cancellous bone 
microarchitecture.  A: Bone Volume (%BV/TV). B: Trabecular Thickness (Tb.Th.). C: 
Trabecular Spacing (Tb.Sp.). D: Trabecular Number (Tb.N.).  Vertical dashed line 
indicates separation of CC from the experimental groups for preliminary ANOVA.  
Those HU groups not sharing the same letter for each variable are significantly different 
from each other (p<0.05); comparisons with CC: †Significantly different vs. CC 
(p<0.05). 
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Fig. 11.  Effects of hindlimb unloading (HU) with or without alendronate (ALEN) 
treatment and/or simulated resistance training (SRT) on cancellous bone cell activity.  A: 
Osteoid Surface (OS/BS). B: Osteoclast Surface (OcS/BS). C: Osteoblast Surface 
(ObS/BS). D: Adipocyte Density (N.Ad/Ma.Ar).  Vertical dashed line indicates 
separation of CC from the experimental groups for preliminary ANOVA.  Those HU 
groups not sharing the same letter for each variable are significantly different from each 
other (p<0.05); comparisons with CC: †Significantly different vs. CC (p<0.05). 
 
 
 
controls (Fig 11 A,B,D).  ALEN treatment exacerbated HU-induced decreases in osteoid 
surface (-80%) and produced a nearly complete suppression of osteoblast surface (-97%) 
vs. CC group.  SRT inhibited disuse-induced reductions in OS/BS and increased 
adipocyte density; the addition of ALEN treatment during SRT significantly lessened the 
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and Ob.S/BS were 61-72% lower vs. those of controls.  On the other hand, Oc.S/BS was 
reduced to a greater extent in HU+SRT/ALEN rats than in all other HU groups. 
 
Osteocyte apoptosis is independently maintained by both muscle contractions and 
alendronate during disuse.  Unloading resulted in a significantly greater percentage of 
apoptotic cancellous osteocytes (+74%) as compared to ambulatory controls (Fig 12).  
SRT and ALEN, independently and in combination, retarded HU-associated increases in 
prevalence of apoptotic osteocytes within cancellous bone.   
 
 
 
Fig. 12.  Effects of hindlimb unloading (HU) with or without alendronate (ALEN) 
treatment and/or simulated resistance training (SRT) on cancellous bone TUNEL+ 
osteocytes (%) measured at the distal femur.  Vertical dashed line indicates separation of 
CC from the experimental groups for preliminary ANOVA.  Those HU groups not 
sharing the same letter for each variable are significantly different from each other 
(p<0.05); comparisons with CC: †Significantly different vs. CC (p<0.05). 
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Discussion 
 The main purpose of our study was to determine if a reduced volume of high 
intensity muscle contractions simulating resistance training (RT), coupled with the anti-
resorptive effects of alendronate (ALEN), would benefit unloaded cancellous bone.  We 
hypothesized that, by combining simulated RT (SRT) and alendronate, the metaphyseal 
bone response would be greater than either of them alone and would result in decreased 
prevalence of apoptotic osteocytes. 
Contrary to our hypothesis, adding alendronate to simulated resistance training 
during disuse did not have a greater positive impact on metaphyseal bone as compared to 
either of these interventions alone.  SRT with ALEN during HU resulted in similar 
changes in proximal tibia bone mass and microarchitecture.  Both the HU+SRT and 
HU+SRT/ALEN groups experienced significant increases in proximal tibia cancellous 
vBMD (Fig 8D), associated with greater bone volume, trabecular thickness and 
trabecular number as compared to untreated HU rats (Fig 9).  Additionally, both exercise 
trained groups exhibited a reduced prevalence of cancellous osteocyte apoptosis (Fig 
12).  However, when simulated RT was added to alendronate treatment during disuse, 
we observed a 70% suppression in cancellous bone formation as measured during the 
final week of disuse (Fig 9C).  Furthermore, ALEN treatment inhibited the dramatic 
response of osteoid and osteoblast cells to SRT (Fig 11 A-B), with values similar to the 
HU-only group.  Since the combined treatment did not provide any advantage in terms 
of cancellous bone mass gains beyond that observed in the HU+SRT animals, our data 
suggest that absolute gains in metaphyseal bone mass in the HU+SRT/ALEN group 
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occurred because of the anabolic effect on bone with the loading provided by these high-
force muscle contractions and not because of anti-resorptive effects of alendronate.         
 Although this is the first study, to our knowledge, to investigate the effects of 
alendronate treatment in conjunction with exercise (engaged without weightbearing) 
during hindlimb unloading, there are a limited number of investigations on this topic 
testing their efficacy during estrogen deficiency using ovariectomized (OVX) rodents.  
Fuchs et al. (112) administered 15 g/kg ALEN (given 2x/week) to OVX rats in 
combination with moderate treadmill running and found that the effects of the combined 
therapy are superior in maintaining bone mass and strength as compared to either 
individual treatment.  Similar to this study, Tamaki et al. (115) documented significant 
interactions between exercise and bisphosphonate treatment on BMD of the proximal 
femur and trabecular bone of the proximal tibia.  These studies, in contrast to our 
investigation, employed moderate intensity treadmill running which has been shown to 
be less effective than resistance exercise at increasing bone mass in rodents (49).  The 
individual and combined effects of 12 months of jump exercise training and daily 
alendronate administration (5 mg/d) on bone mass in post-menopausal women 
demonstrates no additive effects of alendronate and exercise on bone mass or 
mechanical properties, although each treatment was found to independently impact bone 
(116).   
 Combined exercise and alendronate treatment has been investigated in few 
human studies assessing bone loss typically evidenced during long-duration spaceflight.  
The inability of combined anabolic and anti-resorptive therapy to inhibit reductions in 
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disuse-sensitive metaphyseal bone mass has also been documented during bed rest.  
Administration of an early generation bisphosphonate (ethane-1-hydroxy-1-
disphosphonate) combined with treadmill exercise and cycling (modeling exercise 
regimens used by cosmonauts) during 360 days of bed rest reduced negative calcium 
balance, but did not significantly mitigate losses in femoral neck BMD (117).  Neither 
flywheel resistance exercise or pamidronate (another nitrogen-containing 
bisphosphonate was able to rescue metaphyseal bone loss in the tibia during 90 days of 
bed rest (118).  However, combined exercise and bisphosphonate treatment significantly 
mitigates reductions in tibia diaphyseal bone mass.   
 The simulated resistance training protocol utilized in the current study produced 
similar positive effects on the unweighted tibia consistent with our previous results 
(105).  However, lacking detailed histomorphometry data, we were unable to confirm 
that our SRT protocol had an anabolic effect on cancellous bone.  In the current 
investigation, we used a reduced intensity of combined isometric and eccentric muscle 
contractions (75% vs. 100% peak isometric torque), administered fewer training sessions 
(9 vs. 14), and still demonstrated absolute increases in proximal tibia cancellous bone 
vBMD (Fig 8D).  This increase in cancellous bone mass was associated with 
significantly greater bone formation (Fig 9C), osteoid and osteoblast surface (Fig 11A-
B), along with a suppression of the increase in adipocyte density observed in unloaded 
bones (Fig 11D).  Furthermore, simulated RT resulted in greater trabecular thickness as 
compared to both unloaded and ambulatory control animals (Fig 10 B).  However, the 
reduced volume of our training protocol used in this study was not able to mitigate the 
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loss of left ankle plantarflexor muscle mass (Table 1) as did our previous study.  We 
were unable to detect any effect of alendronate treatment on unweighted skeletal muscle.  
Taken together, these data emphasize the dramatic anabolic response of cancellous bone 
to a low volume of high intensity muscle contractions engaged during periods of disuse.  
However, reducing the training intensity and volume (versus our previous protocol) 
resulted in a loss of the mitigating effect on disuse-induced muscle atrophy.   
The effectiveness of alendronate to inhibit disuse-induced bone loss has been 
demonstrated in numerous rodent hindlimb unloading investigations.  Alendronate (0.1 
mg/kg), administered prior to HU, prevented reductions in unweighted bone mass by 
decreasing relative osteoclast surface and mitigating reductions in bone formation (26).  
Furthermore, alendronate treatment during 14-day HU abolished losses in tibia and 
femur BMD, but was unable to rescue disuse-induced reductions in bone strength (65).  
Apseloff et al. (66) administered 0.3 mg/kg alendronate during 28 days of unloading and 
revealed significant reductions in osteoid perimeter, cancellous bone formation, and 
bone resorption during hindlimb unloading.  The resulting increase in bone mass with 
alendronate treatment resulted from greater inhibition of resorption.  Bed rest 
investigations on human subjects testing the effects of alendronate have elucidated 
similar mechanisms of this bisphosphonate’s action on bone during periods of disuse.  
Ruml and colleagues (63) administered 20 mg/day of alendronate during 3 weeks of bed 
rest and observed a reduction in urinary calcium excretion as compared to untreated 
controls.  During a longer duration bed rest investigation (17 weeks), 10 mg/day of 
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alendronate successfully prevented reductions in lumbar spine and femoral neck BMD 
and attenuated increases in urinary markers of bone resorption (64).   
Data from these previous investigations parallel findings in our current study.  
We found that 10 g/kg alendronate (3x/week), given during disuse, maintained both 
total and cancellous vBMD at the proximal tibia, despite lower bone formation and 
osteoid and osteoblast surface.  We were unable to detect significant reductions in 
osteoclast surface in alendronate-treated rodents subjected to unloading.  We did 
measure serum TRACP 5b, a systemic marker of osteoclast activity.  In postmenopausal 
females, serum TRACP 5b correlates significantly with changes in BMD and has been 
accepted as a useful marker for monitoring alendronate treatment (119).  Serum TRACP 
5b was significantly reduced in both HU+ALEN and HU+SRT/ALEN groups as 
compared to unloaded animals (data not shown).  These data suggest that, although 
osteoclast surface measured in our proximal tibia region of interest was not suppressed 
with alendronate treatment during disuse, osteoclast activity across the entire skeleton 
may have been reduced.   
 Similar to previously published results, we found that 28 days of hindlimb 
unloading significantly increased cancellous osteocyte apoptosis (106,120).  However, to 
our knowledge, no prior investigation has defined the role of mechanical loading, 
engaged during a period of imposed disuse, on osteocyte apoptosis within cancellous 
bone.  Basso et al. (107) previously demonstrated that 2 weeks of resumption of normal 
weightbearing after an equal duration of hindlimb unloading returns cancellous 
osteocyte apoptosis to control levels.  Additionally, ulnar loading has been shown to 
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significantly reduce cortical osteocyte apoptosis (121).  Surprisingly, our data 
demonstrate that high intensity muscle contractions completely prevent disuse-induced 
increases in osteocyte apoptosis (Fig 12A).  Furthermore, simulated RT prevented the 
reductions in cancellous bone osteocyte density observed in untreated hindlimb unloaded 
rats (Fig 12B).  Alendronate treatment resulted in a similar protective effect.  Although 
previously published studies have confirmed that alendronate inhibits osteocyte 
apoptosis (61,122), our data are the first to demonstrate the anti-apoptotic effects of 
alendronate during disuse. 
 There were a few limitations to this current investigation.  We were unable to 
detect significant changes in cancellous bone microarchitecture by 2-D 
histomorphometry.  Employing a more sensitive technique of measuring these variables 
may result in more definitive answers to the combined and individual effects of 
simulated RT and alendronate during unloading.  Additionally, our study design did not 
include weightbearing control animals (CC) receiving either simulated RT or 
alendronate; therefore we are unable to determine the important clinical question as to 
whether or not our regimen of alendronate treatment combined with RT has similar 
negative effects on cancellous bone formation in weightbearing rodents.   
 In conclusion, data from this study suggests that bisphosphonate treatment, when 
combined with high-intensity muscle contractions during disuse, significantly reduces 
the anabolic response of cancellous bone to simulated resistance training.  This 
beneficial effect of mechanical loading and alendronate treatment (acting independently 
and in combination) may be affected in part by inhibiting disuse-associated increases in 
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cancellous osteocyte apoptosis.  The suggested inhibitory effects of bisphosphonate 
treatment on the cancellous bone formation response to high intensity resistance exercise 
has important implications for the efficacy of exercise countermeasures utilized during 
periods of disuse in any population using these pharmaceutical agents. 
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CHAPTER V 
ADMINISTRATION OF A BETA-1 ADRENERGIC AGONIST ATTENUATES 
METAPHYSEAL BONE LOSS DURING UNLOADING BY MAINTAINING 
FORMATION 
 
Introduction 
Mechanical loading is essential to maintain bone mass during periods of disuse 
(i.e. bedrest or casting) or reduced weightbearing activity.  Long duration exposure to 
microgravity leads to an accelerated loss of bone mass (~1-2%/month) and results in 
osteopenia (13,14).  For those astronauts experiencing the greatest bone loss, reductions 
in modeled proximal femur strength after 6 months of microgravity exposure approach 
the estimated lifetime loss in stance strength for Caucasian women (16,17).  Ground-
based models demonstrate similar deleterious effects when mechanical loading of 
weightbearing bones ceases.  Prolonged bed rest reduces femoral neck, lumbar spine, 
and lower body bone mineral density (BMD), resulting in decreased bone volume 
fraction (BV/TV) and trabecular thickness (Tb.Th) (54,123).  In addition, spinal cord 
injury (SCI) patients experience severe reductions in bone, predominantly in cancellous 
bone compartments (124-126).   
The rodent hindlimb unloading (HU) model is a well-established ground-based 
model for investigating disuse effects on bone and muscle (20).  Hindlimb unloading 
results in significant reductions in disuse-sensitive cancellous bone mass, architecture 
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and material properties due to early increases in bone resorption followed by prolonged 
depression of bone formation rate (BFR) (21-24,104,105). 
Beta-adrenergic receptor agonists, activated by the sympathetic nervous system 
(SNS), may affect bone metabolism through separate avenues and elicit opposing effects 
on bone mass.  Three subunits of β-adrenergic receptors (Adrb1, 2, 3) are present in 
tissues within the body.  Adrb2 receptors present in the lungs mediate bronchiolar 
dilation; those on osteoblasts and osteoclasts stimulate apoptosis and result in diminished 
bone mass (67,68).  Adrb1 receptors on the heart, increase cardiac contractility when 
activated, and are also present on osteoblasts and osteoclasts (69,70).  Activation of β-3 
adrenergic receptors, the primary adrenoreceptor on adipocytes, upregulates lipolysis 
(71,72).   
Adrb1 and Adrb2 receptors are both present on osteoblasts, but β-2 adrenergic 
receptors are the predominant subtype (67,68,73-75).  Adrb2 receptor agonist 
administration leads to increased bone resorption, resulting in reduced cancellous bone 
mass and negative changes to microarchitecture (78,79).  Stimulation of Adrb2 receptors 
on osteoblasts increases osteoclast differentiation and activity (81).  Salbutamol, an 
Adrb2 receptor agonist, is unable to inhibit the deleterious effects of ovariectomy-
induced cancellous bone loss (80).  In addition, Adrb2 receptor knock-out (KO) and 
Adrb1 receptor KO mice demonstrate a high and low bone mass phenotype, 
respectively, whereas Adrb1/2 receptor double-KO mice exhibit a marked reduction in 
cancellous BFR vs. wild types (67,82,127).  Adrb1 receptor deficient mice do not 
respond to mechanical loading, whereas Adrb2 receptor deficient and wild-type 
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littermates were found to respond normally (82).  Taken together, these data suggest that 
the high bone mass phenotype in Adrb2 receptor KO mice may be caused by enhanced 
β-1 adrenergic receptor activity stimulating bone formation in the absence of the 
inhibitory effects of β-2 adrenergic receptors on osteoblasts.  Therefore, the role that 
Adrb1 receptor stimulation during reduced mechanical loading has on disuse-sensitive 
cancellous bone is important to further understanding the underlying mechanisms 
responsible for bone loss. 
Dobutamine (DOB) is a non-specific, Adrb receptor agonist with dominant β-1 
adrenergic receptor activity and a small amount of Adrb2 activity (76).  Its ability to 
primarily activate Adrb1 and makes it an attractive synthetic catecholamine to study in 
coordination with HU.  Our previous data demonstrated that DOB administered during 
HU significantly blunts disuse-induced reductions in femoral midshaft bone area and 
cross-sectional moment of inertia (CSMI) by mitigating the decline in periosteal bone 
mineral apposition rate (MAR) (77).   
Our aim with these experiments was to elucidate the mechanisms by which an 
Adrb1 agonist (DOB) mitigates losses bone (tibia) mass and strength during HU in 
skeletally mature rats.  Secondary to this, we sought to characterize Adrb1 agonist 
effects on unloaded skeletal muscle strength and lean tissue mass.  We hypothesized that 
DOB treatment during HU would diminish HU-associated reductions in bone mass and 
strength, and that the effects of DOB treatment would be greater during normal 
gravitational loading.   
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Materials and Methods 
Animals and Experimental Design  
 
Forty-eight male Sprague-Dawley rats were obtained from Harlan (Houston, TX) 
at 6 months of age and allowed to acclimate to their surroundings for 14 days prior to 
initiation of the study.  All animals were acclimated to their surroundings for 14 days, 
and were then singly housed in a temperature-controlled (23 ± 2ºC) room with a 12-hour 
light-dark cycle in an American Association for Accreditation of Laboratory Animal 
Care-accredited animal care facility, where standard rodent chow (Harlan Teklad 8604) 
and water were provided ad-libitum.  Animal care and all experimental procedures 
described in this investigation were approved by the Texas A&M University Institutional 
Animal Care and Use Committee. 
One day prior to initiation of experimental treatments, all animals underwent 
peripheral quantitative computed tomography (pQCT) scans and were rank ordered by 
total volumetric bone mineral density (vBMD) of the proximal tibia metaphysis (PTM) 
and randomly assigned to one of two activity groups: normal ambulatory cage activity 
(CC; n=24) or hindlimb unloading (HU; n=24).  Within each activity group, rats were 
randomly assigned to receive daily intraperitoneal injections of dobutamine (DOB; 4 
mg/kg body mass/d; n=12) or an equal volume of saline (VEH; n=12), administered 
within the first 2 hours of the animals’ dark cycle.  The one bolus dose of DOB was 
found to be effective at mitigating reductions in cancellous vBMD at the PTM during 
28-day HU in a small pilot study (unpublished data).  Dobutamine hydrochloride 
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solution (Sigma-Aldrich Corp., St. Louis, MO) was made daily with sterile saline and 
stored at 4ºC until use.   
Calcein injections (25 mg/kg body mass) were given subcutaneously on 9 and 2 
days prior to sacrifice to label mineralizing bone for histomorphometric analyses.  HU 
animals were anesthetized before removal from tail suspension at the end of the study to 
prevent any weight bearing by the hindlimbs.  At necropsy, both right and left soleus, 
plantaris, and gastrocnemius muscles were excised and wet weights were recorded.  
Right tibia and femur were removed, cleaned of soft tissue, and stored at -80°C in PBS 
soaked gauze for ex vivo pQCT scans and/or mechanical testing, whereas left tibia were 
stored in 70% ethanol at 4°C for histology.  Additionally, adrenal glands were dissected 
free and wet weights obtained as a marker of stress; heart wet weight was also recorded.  
 
Hindlimb Unloading 
Hindlimb unloading was achieved by tail suspension as previously described 
(21,103,105).  Briefly, while the rat was under anesthesia, the tail was cleaned and dried 
thoroughly.  A thin layer of adhesive (Amazing Goop, Eclectic Products, LA) was 
applied to the proximal half of the tail along the medial and lateral sides.  A standard 
porous tape (Kendall, Mansfield, MA) harness was pressed firmly to the glue and 
allowed to dry (~30 min).  A paper clip was used to attach the animal’s tail harness to a 
swivel apparatus on the wire spanning the top of an 18” x 18” x 18” cage.  The height of 
the animal’s hindquarters was adjusted to prevent any contact of the hindlimbs with the 
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cage floor, resulting in approximately a 30° head-down tilt.  The forelimbs of the animal 
maintained contact with the cage bottom, allowing the rat full access to the entire cage.     
 
Muscle Function Testing 
 Peak isometric torque of the left leg plantarflexor muscles was determined on 
day 28 on all animals using an isokinetic dynamometer as previously described (128).  
Briefly, animals were anesethetized with isoflurane gas (~2.5%) mixed with oxygen 
while remaining suspended to prevent any weight bearing of the hindlimbs.  Each rat 
was then placed in right lateral recumbency on a platform, the left foot was secured onto 
the foot pedal, and the left knee was clamped so that the lower leg was perpendicular to 
the foot and the femur and tibia were at right angles to each other.  Plantarflexor muscle 
stimulation was performed with percutaneous electrodes inserted straddling the sciatic 
nerve in the proximal thigh region.  The stimulation
 
wires were then attached to the 
output poles of a Grass Instruments stimulus
 
isolation unit (Model SIU5; Astro-Med, 
Inc; W. Warwick, RI) interfaced with a stimulator (S88; Astro-Med, Inc; W. Warwick, 
RI), which delivered current to the sciatic nerve and induced muscle contraction.    
 
Peripheral Quantitative Computed Tomography (pQCT) 
On days -1 and 28 of the study, tomographic scans were performed in vivo at the 
proximal and mid-diaphysis of the left tibia with a Stratec XCT Research-M device 
(Norland Corp., Fort Atkinson, WI), using a voxel size of 100 μm and a scanning beam 
thickness of 500 μm.  Daily calibration of this machine was performed with a 
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hydroxyapatite standard cone phantom.  Transverse images of the left tibia were taken at 
5.0, 5.5, and 6.0 mm from the proximal tibia plateau, as well as one slice at the midshaft 
(50% of the total tibia length).  A standardized analysis for either metaphyseal bone 
(contour mode 3, peel mode 2, outer threshold of 0.214 g/cm
3
, inner threshold of 0.605 
g/cm
3
) or diaphyseal bone (separation 1, threshold of 0.605 g/cm
3
) was applied to each 
slice.   
For ex vivo scans, thawed femur and humeri were placed in a 1 mol/L PBS-filled 
vial to maintain hydration during the scan, after which time they were returned to the -
80°C freezer.  Femoral neck scanning was performed with the  bone shaft, wrapped in 
PBS-soaked gauze, positioned on a platform with only the neck exposed in order to scan 
slices (2 images, 0.5 mm apart) perpendicular to the femoral neck’s long axis.  
Additionally, one scan slice was taken at the femur mid-diaphysis.  Femoral neck slices 
were analyzed using contour mode 3, peel mode 5, and attenuation threshold 0.214 
g/cm
3
.  Scan speed was set at 2.5 mm/sec with a voxel resolution of 0.07 x 0.07 x 0.50 
mm. 
Values of total volumetric bone mineral density (vBMD), total bone mineral 
content (BMC) and total bone area were averaged across slices at each metaphyseal bone 
site to yield a mean value.  Additionally, mid-diaphyseal cross-sectional moment of 
inertia (CSMI) was obtained with respect to the neutral bending axis during three-point 
bending for later calculation of material properties.  Machine precision (based on 
manufacturer’s data) is and  9 mg/cm3 for cortical BMD.  Coefficients of variation 
were  0.6, 1.6, and 1.9% for in vivo proximal tibia total vBMD, total BMC, and total 
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area, respectively, as determined from repeat scans on each of (n=6) adult male rats.  In 
vivo coefficients of variation for cortical vBMD (0.7%), cortical BMC (1.2%), cortical 
bone area (1.5%), and CSMI (3.0%) were determined in a similar manner as described 
above.   
 
Dual –Energy X-Ray Absorptiometry (DEXA) 
 One day before both initiation and cessation of the investigation, all animals were 
anesthetized with ketamine/medetomidine cocktail (ketamine 50 mg/kg, medetomidine 
0.5 mg/kg) and dual-energy x-ray absorptiometry (DEXA; GE Lunar Prodigy  using 
small animal software) scans were completed to assess changes in whole body 
composition (lean mass, fat mass).  In vivo total body coefficients of variation for lean 
mass and fat mass are 1.07 and 2.99%, respectively, as determined from repeat scans on 
each of adult male rats (n=6).   
 
Histomorphometry Analyses 
 Undemineralized proximal left tibia were subjected to serial dehydration and 
embedded in methylmethacrylate (Aldrich M5, 590-9).  Serial frontal sections were cut 8 
μm thick and left unstained for fluorochrome label measurements.  Additionally, 4 μm 
thick sections for von Kossa staining for measurement of cancellous bone volume 
normalized to tissue volume and quantification of osteoid, osteoblast, and osteoclast 
surfaces as a percent of total cancellous surface.  The histomorphometric analyses were 
performed by using the OsteoMeasure Analysis System, Version 1.3 (OsteoMetrics, 
84 
 
 
Atlanta, GA).  A defined region of interest was established ~1 mm from the growth plate 
and within the endocortical edges encompassing 8-9 mm
2 
at x40 magnification.  Total 
bone surface (BS), single labeled surface (SLS), double-labeled surface (DLS), interlabel 
distances, bone volume, and osteoid/osteoclast/osteoblast surfaces were measured at 
x200 magnification.  Mineral apposition rate (MAR, μm/day) was calculated by dividing 
the average inter-label width by the time between labels (7 days); mineralizing surface 
(MS) for cancellous bone surfaces (BS) was calculated using the formula %MS/BS = 
{[(SLS/2) + DLS]/surface perimeter} X 100.   Bone formation rate (BFR) was calculated 
as (MAR x MS/BS).   
 
Biomechanical Testing 
Femur and tibia mid-diaphyseal cortical bone mechanical properties were 
determined using three-point bending to failure and femoral neck maximal force 
measured on an Instron 1125 machine as previously described (129). Sites of mechanical 
testing were matched to pQCT sampling sites (e.g., the femoral mid-diaphyses were 
analyzed at 50% of total bone length).  Prior to testing, the length of each specimen was 
measured and the half-length was marked with Absolute Digamatic calipers (Mitutoyo 
Corp., Japan).  In addition, the anterioposterior (AP) and mediolateral (ML) surface 
diameters at each testing site were similarly measured at the previously marked mid-
point.  On the day of testing, bones were thawed at room temperature and placed either 
anterior (femur) or lateral (tibia) side down on metal pin supports located ±9 mm (tibia) 
and ±7.5 mm (femur) from the predetermined mid-diaphysis testing site.  All specimens 
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were sprayed with PBS immediately preceding testing to maintain hydration.  Femoral 
necks were tested by placing the distal portion of the proximal half of the femur 
perpendicularly into a metal fixture and loading the femoral head in vertical direction, 
parallel to the long axis of the femur (129).  Loading of the femoral head in this fashion 
creates a combination of bending, shear, and compression.  Using a 1,000 lb load cell 
calibrated to 100 lb maximum load, all tests used quasi-static loading at a rate of 2.54 
mm/min applied to the posterior surface of the femora, the medial surface of the tibia or 
the femoral head until fracture. Displacements of the servo-controlled Instron were 
monitored by a linear variable differential transformer (LVDT) interfaced with a 
personal computer (Gardener Systems software).   
Raw data, collected at 10 Hz as load vs. displacement curves, were analyzed with 
Table-Curve 2.0 (Jandel Scientific; San Rafael, CA).  Structural variables were obtained 
directly from load/displacement curves. The maximum load attained was defined as 
maximum force (MF) and the slope of the elastic portion of the curve defined as stiffness 
(S).  Yield force (90%) was ascribed as a 10% deviation from the slope of the elastic 
portion of the load/displacement curve.  Material properties of tibia and femur were 
calculated as previously described (swift jbmr 2010).  Briefly, structural properties were 
normalized to bone geometry at the site of testing using cross-sectional moment of 
inertia (CSMI; from pQCT), bone diameter (D) measured by calipers, and a support span 
distance of either 18mm (tibia) or 15mm (femur).  Formulas for elastic modulus (EM) 
and ultimate stress (US) were as follows: EM = (S x support span
3
) / (48 x CSMI x 
1,000); US = [MF x support span x (D / 2)] / (4 x CSMI). 
86 
 
 
Statistical Analyses 
 
All data were expressed as means ± SEM and statistical relationships were 
evaluated using the statistical package SPSS (v.15).  In vivo pQCT, DEXA, and body 
mass data were analyzed using a three-factor ANOVA (drug, gravity condition, time) 
with repeated measures on time.  Paired t-tests were used on absolute values of in vivo 
pQCT and DEXA pre- and post-values to determine if the change score represented a 
significant change from Day 0.  Mechanical testing, ex vivo pQCT, plantarflexor muscle 
strength, tissue masses, and histomorphometry data were analyzed using a two-factor 
ANOVA (drug, gravity condition).  When a significant main effect was found, Tukey’s 
post-hoc analyses were performed for pair-wise comparisons.  For all data, statistical 
significance was accepted at p<0.05. 
 
Results 
Adrb1 receptor agonist treatment rescues unloading-associated reductions in 
muscle strength but not body mass.  Significant reductions in body mass during HU (-
3%) were accompanied by decrements in whole-body fat (-18%) by 28 days (Figure 13).  
HU rats did not exhibit the small non-significant lean mass gains observed in 
weightbearing cage controls.  Dobutamine administration during unloading had no 
impact on HU-associated reductions in body mass; however, HU rats treated with DOB 
lost significantly more fat mass (- 37%).  DOB treatment led to significantly higher 
cardiac mass in ambulatory controls (+7% vs. CC-VEH) but no differences in adrenal 
mass were evident among groups (Table 4). 
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Fig. 13.  Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on changes in body and tissue masses 
as measured by in vivo DEXA scans on days -1 and 27.  Values are group mean  
standard error of the mean.  Those groups not sharing the same letter for each variable 
are significantly different from each other (p<0.05); 
*
p<0.05 vs. day 0 value.     
 
 
Mechanical unloading resulted in a significant 9.7% reduction in peak isometric 
torque in HU-VEH rats vs. ambulatory controls (p<0.05).   DOB treatment attenuated 
HU-associated losses in this measure of muscle strength compared to both CC groups 
(Fig 14).   
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Table 4.  Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on cardiac and adrenal mass. 
 
 
 
CC: normal ambulatory aging controls; HU: hindlimb unloaded; VEH: vehicle (saline) 
administration; DOB: dobutamine administration (4 mg/kg BW/d, one bolus injection).  
Values presented are group mean  standard error of the mean.  Those groups not 
sharing the same letter for each variable are significantly different from each other 
(p<0.05).  Group means with no labels are not statistically different.   
 
 
 
Loss in bone mass and changes in bone geometry with disuse is attenuated with 
Adrb1 treatment.  In vivo pQCT scans on days -1 and 28 revealed significant 
reductions in total BMC (-17%), total bone area (-8%), and total vBMD (-9%) at the 
PTM attributable to unloading (HU-VEH group) (Fig 15A-C).  Dobutamine 
administration during HU (HU-DOB) was unable to mitigate associated reductions in 
both total BMC (-16%) or total bone area (-10%), but did significantly attenuate the loss 
in total vBMD (vs. HU-VEH).  Additionally, beta-adrenergic agonist treatment 
significantly increased total bone area (+5%) at the PTM (Fig 15B) in weightbearing 
controls.  
 
         CC   HU 
  VEH DOB   VEH DOB 
Tissue Mass (g) 
     Cardiac  1.350 ± 0.038
a
 1.442 ± 0.031
b
 
 
1.294 ± 0.038
a
 1.375 ± 0.039
ab
 
Adrenal  0.030 ± 0.003 0.030 ± 0.001   0.041 ± 0.010 0.061 ± 0.027 
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Fig. 14.  Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on in vivo measurement of peak 
isometric torque of the ankle plantarflexor muscles.  VEH groups are represented by 
black bars; DOB groups are represented by gray bars.  Values are group mean  standard 
error of the mean.  Those groups not sharing the same letter for each variable are 
significantly different from each other (p<0.05).  
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Fig. 15.  Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on changes in structural and geometric 
properties of the proximal tibia metaphysis as taken by in vivo peripheral quantitative 
computed tomography scans.  A: Total bone mineral content (BMC). B: Total bone area. 
C: Total volumetric bone mineral density (vBMD).  VEH groups are represented by 
black bars; DOB groups are represented by gray bars.  Those groups not sharing the 
same letter for each variable are significantly different from each other (p<0.05); 
*p<0.05 vs. day 0 value. 
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Fig. 16.  Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on structural and geometric properties 
of the femoral neck as taken by ex vivo peripheral quantitative computed tomography 
scans.  A: Total bone mineral content (BMC). B: Total volumetric bone mineral density 
(vBMD). C: Total bone area.  VEH groups are represented by black bars; DOB groups 
are represented by gray bars.  Those groups not sharing the same letter for each variable 
are significantly different from each other (p<0.05).   
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Ex vivo scans of the femoral neck revealed that DOB administration during HU 
resulted in significantly greater total BMC and total bone area (18 and 23%, 
respectively) compared to the HU-VEH group (Fig 16A-B).  However, significant HU-
induced reductions in total vBMD; this loss was not affected by DOB treatment (Fig 
16C).  There were no effects of Adrb1 treatment on femoral neck bone in ambulatory 
cage activity animals. 
 In vivo pQCT scans of the mid-diaphysis tibia yielded no significant effects on 
changes in cortical bone structure and geometry with unloading or normal cage activity.  
However, daily administration of DOB during HU (HU-DOB) significantly increased 
cortical vBMD (+2%) (data not shown).  No changes in tibia cortical bone parameters 
were evidenced in either ambulatory group.     
The effects of disuse and/or Adrb1 treatment on mid-diaphyseal femur cortical 
bone structure and geometry yielded no significant differences among any of the 
treatment groups for cortical BMC, cortical area, cortical vBMD, or CSMI (data not 
shown).   
 
Cancellous bone formation is maintained with Adrb1 receptor agonist 
administration during unloading.  Hindlimb unloading significantly reduced 
%MS/BS, MAR, and BFR in proximal tibia cancellous bone (Fig 17A-C) by 43%, 26%, 
and 56%, respectively, vs. that observed in the CC-VEH group.  In hindlimb unloaded 
animals given daily dobutamine treatments, %MS/BS (+105%) and MAR (+35%) were 
significantly greater than that measured in VEH-treated HU rats (Fig 17A-B).  Most  
93 
 
 
 
 
Fig. 17.  Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on cancellous bone dynamic 
histomorphometry analyses measured at the proximal tibia metaphysis.  A: Mineralizing 
Surface (%MS/BS). B: Mineral Apposition Rate (MAR). C: Bone Formation Rate 
(BFR).  VEH groups are represented by black bars; DOB groups are represented by gray 
bars.  Those groups not sharing the same letter for each variable are significantly 
different from each other (p<0.001).     
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strikingly, cancellous BFR at the PTM was 168% higher in HU-DOB vs. vehicle-treated 
HU rats (Fig 17C).   All three cancellous bone dynamic histomorphometry properties 
were completely restored to ambulatory control group values by Adrb1 treatment during 
disuse.   DOB administration during normal cage activity did not alter %MS/BS, MAR, 
or BFR at the PTM.  Rare fluorochrome labels were present on trabecular surfaces of 
HU rats (Fig 18A), whereas DOB treatment during HU resulted in a large amount of 
labeling (Fig 18B). 
 
 
  
 
Fig. 18.  Visual depiction (100x) of calcein labeling on the surface of cancellous bone 
located at the proximal tibia metaphysis.  A: HU+VEH B: HU+DOB.  Note the extensive 
flurochrome labeling (arrows) in HU+DOB and large interlabel width. 
 
 
Adrb1 agonist treatment increases both tibia and femur bone strength during 
disuse.  Mechanical testing of mid-diaphysis femur revealed a 14% reduction in HU- 
A. B.
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Table 5.  Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on mechanical properties of mid-
diaphysis tibia and femur and femoral neck. 
 
 
 
CC: normal ambulatory aging controls; HU: hindlimb unloaded; VEH: vehicle (saline) 
administration; DOB: dobutamine administration (4 mg/kg BW/d, one bolus injection).  
Values presented are group mean  standard error of the mean.  Those groups not sharing 
the same letter for each variable are significantly different from each other (p<0.05).  
Group means with no labels are not statistically different.   
      
  CC   HU 
  VEH DOB   VEH DOB 
Mid-diaphysis Tibia 
     Max Force (N) 120.9 ± 4.5
bc
 125.5 ± 6.6
ab
 
 
119.9 ± 3.9
bc
 137.7 ± 4.1
a
 
Yield Force (N) 100.6 ± 5.4
ab
 101.5 ± 4.7
ab
 
 
94.0 ± 2.8
b
 105.6 ± 3.6
a
 
Elastic Modulus (GPa) 1.6 ± 0.1 1.5 ± 0.1 
 
1.6 ± 0.1 1.6 ± 0.1 
Ultimate Stress (MPa) 104.1 ± 3.7 102.9 ± 4.3 
 
102.8 ± 5.2 114.2 ± 7.0 
Energy to Max Force (N/mm) 137.3 ± 13.0
a
 139.6 ± 10.8
a
 
 
149.1 ± 7.6
ab
 162.9 ± 8.2
b
 
      Mid-diaphysis Femur 
     Max Force (N) 246.4 ± 12.3
ab
 253.7 ± 10.8
a
 
 
217.9 ± 11.5
b
 241.2 ± 8.0
ab
 
Yield Force (N) 188.3 ± 5.8
a
 184.8 ± 8.3
a
 
 
166.5 ± 6.5
b
 159.2 ± 10.6
b
 
Elastic Modulus (GPa) 4.8 ± 0.2
a
 4.7 ± 0.2
ab
 
 
4.3 ± 0.2
b
 4.4 ± 0.3
ab
 
Ultimate Stress (MPa) 66.2 ± 6.9
ab
 67.8 ± 6.4
a
 
 
63.8 ± 3.1
a
 62.4 ± 6.4
ab
 
Energy to Max Force (N/mm) 102.3 ± 9.7
ab
 106.1 ± 9.0
a
 
 
79.2 ± 9.2
a
 93.1 ± 4.9
ab
 
      Femoral Neck 
     Max Force (N) 95.1 ± 5.8
a
 87.4 ± 5.2
ab
   81.3 ± 4.3
b
 101.4 ± 5.2
a
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VEH maximum force vs. CC-DOB (Table 5).  Additionally, hindlimb unloading 
significantly reduced femur elastic modulus by 10% vs. ambulatory cage controls (CC- 
VEH).  DOB treatment during disuse inhibited  reductions in mid-diaphysis femur 
maximum force and elastic modulus.  Dobutamine treatment during hindlimb unloading 
significantly enhanced tibial mid-diaphysis maximum and yield forces vs. HU-VEH 
(+10 and 12%, respectively).   
 Hindlimb unloading significantly reduced femoral neck maximum force (15%) 
vs. CC-VEH.  This reduction in strength was abolished by DOB treatment during HU, 
resulting in a 25% higher max force vs. the mean value in HU-VEH animals (Table 5). 
 
Discussion 
The main objective of this study was to determine the effects of a beta-1 
adrenergic agonist (Adrb1) on disuse-induced bone loss.  We hypothesized that daily 
treatment of dobutamine (DOB), an Adrb1 agonist, during hindlimb unloading (HU) 
would diminish disuse-associated reductions in unweighted bone mass, and strength, and 
that these effects would be enhanced during normal gravitational loading.   
 This experiment is the first to demonstrate that DOB administration during disuse 
significantly blunts the catabolic effect of HU on bone mass at a mixed bone site 
(proximal tibia).  Most significantly, daily DOB treatment during HU not only 
attenuated but abolished reductions in cancellous bone formation at the proximal tibia 
metaphysis (PTM) observed in vehicle-treated HU rats; both , mineral apposition rate 
and % mineralizing surface were enhanced as compared to HU-VEH (Fig 17A-C).  
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Additionally, we observe similar effects of this beta-agonist on disuse bone loss at 
another mixed bone site (femoral neck) in the unloaded hindlimb (Table 5; Fig 16A).  
The maintenance of bone formation at the PTM in the HU-DOB group mitigated 
reductions in vBMD as compared to vehicle (VEH) treatment (Fig 15C).  DOB 
treatment during HU also resulted in significant fat, but not lean mass losses, resulting in 
significant reductions in total body mass (Fig 13).  Furthermore, dobutamine 
administration during unloading attenuated reductions in lower leg muscle strength (Fig 
14).  Thus, our data demonstrate that daily Adrb1 agonist administration during disuse 
can effectively mitigate reductions in metaphyseal bone mass by maintaining cancellous 
bone formation.   
 Previous studies testing the efficacy of β-2 adrenoreceptor agonists have found 
no benefit in preventing bone loss due to estrogen deficiency or to disuse.  Salbutamol, a 
selective Adrb2 agonist, is unable to inhibit ovariectomy-induced reductions in femur 
BMD and trabecular bone microarchitecture, resulting in decreased trabecular number 
and thickness (80).  Zeman et. al. (130) demonstrated the ineffectiveness of another 
Adrb2 agonist, clenbuterol, in attenuating losses in tibia or femur bone mass during 
hindlimb unloading or in ovariectomized rats.  However, clenbuterol was able to 
mitigate reductions in lower leg bone mass after surgical denervation.  These data 
suggest that activation of Adrb2 receptors during reduced mechanical loading or 
estrogen deficiency does not result in any beneficial effects on cancellous bone. 
 We speculate that the positive effects of a β-1 adrenergic receptor agonist 
treatment on metaphyseal bone during disuse may be a function of reduced prevalence of 
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osteoblast and osteocyte apoptosis.  Reductions in metaphyseal bone mass during 
hindlimb unloading are associated with significant and immediate increases in 
cancellous and cortical osteocyte apoptosis in unweighted proximal tibiae by day 3 of 
HU, which effect persisted for 18 days (106,107,120).  Isoproterenol, an Adrb agonist 
(equally stimulating Adrb1 and Adrb2 receptors) has anti-apoptotic effects on cultured 
osteoblasts (131).  Adrb1 stimulation may attenuate increases in mechanosensing 
osteocytes and osteoblasts, providing an explanation for the lack of reduction in 
cancellous bone formation in unloaded animals administered dobutamine.  Evaluation of 
changes in osteocyte and osteoblast apoptosis, as well as bone marrow stromal cell 
differentiation within metaphyseal region of unweighted bone would be desirable. 
 We hypothesized that DOB treatment would mitigate reductions in bone mass 
during HU and that any effects on bone geometry or mass would be further enhanced 
with normal weightbearing activity in control animals.   Although we did demonstrate 
that Adrb1 receptor agonist treatment attenuated reductions in disuse-sensitive 
metaphyseal bone, our data do not support the latter hypothesis.  Dobutamine given 
during normal gravitational loading did not stimulate any additional gains in cortical or 
cancellous bone mass or strength as compared to the CC-VEH group.  Cancellous bone 
mineralizing surface was greater in animals treated with DOB, but without any 
concordant effect on mineral apposition rate, there was no increase in bone formation 
rate (Fig 17 A,C). 
Data from this investigation demonstrates no deleterious effects of beta-1 
adrenergic agonist administration on bone during normal ambulatory activity.  There 
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was a significant decrease in CC-DOB total vBMD at the proximal tibia, but this 
reduction was not significantly different from the CC-VEH group (Fig 15C).  
Furthermore, the mild reduction in CC-DOB total vBMD was attributable to a greater 
increase in proximal tibia total bone area as compared to total BMC (Fig 15A-B).  
Numerous other investigations have revealed significant reductions in bone mass and 
microarchitecture with β-2 adrenergic agonist administration.   Previous studies have 
observed diminished tibia and femur metaphyseal BMD, trabecular bone 
microarchitecture, and diaphyseal bone strength in animals chronically administered 
clenbuterol or salbutamol (78,79,132).  These detrimental effects are attributable to an 
increase in bone resorption, and not reduced formation (133).  Contrary to these results, 
our data demonstrate that Adrb1 agonist administration does not result in deleterious 
effects on cortical or cancellous bone during normal gravitational loading, consistent 
with our previous findings (77). 
 Data from this investigation indicate that, during a period of reduced mechanical 
loading, dobutamine’s effects are more pronounced in primarily cancellous bone 
compartments than at cortical bone sites.  Hindlimb unloaded animals given DOB 
exhibited mitigated reductions in proximal tibia vBMD (Fig 15C) and higher cancellous 
bone formation than in vehicle-treated unloaded animals (Fig 17C).  Most significantly, 
femoral neck BMC and bone area (Fig 16), and maximal force during mechanical testing 
were greater in dobutamine-treated HU rats vs. vehicle-treated unloaded animals, 
contributing to significantly higher femoral neck strength in the former group (Table 5).  
The only benefits observed to purely cortical bone sites were a slight increase in tibia 
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cortical vBMD (data not shown) and mid-diaphysis bone strength (Table 5); otherwise, 
Adrb1 agonist treatment during disuse did not result in any further enhancement of 
cortical bone properties.   
There were several limitations in the current study.  This investigation utilized a 
non-specific Adrb agonist (dobutamine), which may have some effects on beta 2 
receptor-mediated functions.  Although dobutamine functions primarily as an Adrb1 
agonist, future studies involving a specific Adrb1 agonist are necessary for definitively 
characterizing these effects.  Beta-2 adrenergic (Adrb2) stimulation increases bone 
resorption and results in significantly reduced bone mass, whereas Adrb2-deficient mice 
display a high bone mass phenotype with increased cancellous BV/TV as compared to 
wild-type littermates (67,69).  Dobutamine’s ability to stimulate Adrb2’s on osteoblasts 
may have contributed to the reduced metaphyseal vBMD during unloading as compared 
to ambulatory controls (Fig 15C).  An Adrb1 agonist, with no stimulation of Adrb2s, 
may demonstrate greater attenuation in losses of cancellous bone during disuse.  
Secondly, in this study, we did not assess the effect DOB administration on trabecular 
bone microarchitecture.  Assessment of metaphyseal bone structure and bone cell 
surfaces are necessary to fully elucidate the effects of Adrb1 receptor agonist stimulation 
on metaphyseal bone during disuse.   
The ability of DOB to attenuate reductions in metaphyseal bone mass during 28-
day HU may be related to some mitigation of the reduced blood flow to bone during 
unloading.  Perfusion pressure and increased vascular resistance in unweighted tibia and 
femur bones are observed within 10 minutes of assuming the head-down posture of 
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hindlimb unloading, with maintained adverse effects with 28 days of continued 
suspension (134).  Distal femur and proximal tibia blood flow are reduced by ~40% after 
a 28-day HU protocol (135).  Dobutamine has previously been shown to increase 
hindlimb blood flow during normal ambulation (136).  Maintained bone blood flow to 
unweighted tibiae with DOB treatment may be an alternate explanation for the 
attenuated reductions in metaphyseal bone mass. 
In summary, β-1 adrenergic receptor agonist administration during disuse 
attenuates reductions in metaphyseal bone mass by effectively maintaining cancellous 
bone formation.  Dobutamine treatment significantly increased mid-diaphyseal tibia 
cortical vBMD in and during 28-day HU, resulting in increased bone strength as 
compared to VEH-treated unloaded rats.  Importantly, contrary to documented effects of 
β-2 agonist treatment, we found no deleterious effects of dobutamine on cortical or 
cancellous bone with normal ambulation.  These data demonstrate a potential role for β-
1 adrenergic signaling in the bone response to mechanical unloading.  Further 
investigations are necessary to define the exact mechanisms responsible for the positive 
effects of dobutamine or more specific Adrb1 agonists on disuse-induced bone loss. 
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CHAPTER VI 
BETA-ADRENGERIC AGONIST ADMINISTRATION MITIGATES NEGATIVE 
CHANGES IN CANCELLOUS BONE MICROARCHITECTURE AND INIHIBITS 
OSTEOCYTE APOPTOSIS DURING DISUSE 
 
Introduction 
Osteoporosis is a debilitating skeletal disorder reportedly affecting nearly 44 
million in the United States alone (137).  Fragility fractures common in those with 
advanced osteoporosis can result in a reduced quality of life (138-141).  Recently, it has 
been estimated that the cost associated with treating new osteoporotic fractures in the US 
will total $16.9 billion (142).  Furthermore, a significant number of osteoporotic patients 
are bedridden, resulting in greater risk for debilitating secondary physiological effects 
and even death (143). 
Similar to the effects of prolonged bed rest in humans, rodent hindlimb unloading 
(HU) significantly reduces cancellous bone mass and leads to deleterious changes in 
microarchitecture due to early increases in bone resorption followed by prolonged 
depressions in bone formation rate (BFR) (21-24).  Unloading-associated reductions in 
metaphyseal bone mass are associated with increased osteocyte and osteoblast apoptosis.  
Dramatic increases are observed in the number of apoptotic osteocytes in cancellous 
bone as early as 3 days after initiation of HU (106,107).  Additionally, HU increases the 
Bax/Bcl-2 (pro- and anti-apoptotic proteins) ratio by 2-fold in metaphyseal bone which 
may be responsible for the increased prevalence of osteoblast and osteocyte apoptosis 
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(120).  Isoproterenol, an Adrb agonist (equally stimulating Adrb1 and Adrb2 receptors), 
has been found to have anti-apoptotic effects on cultured osteoblasts (131).  Taken 
together, these data suggest that reducing osteocyte apoptosis during the early stages of 
unloading may be an effective strategy to preserve cancellous bone mass and maintain 
osteoblast function.   
Although stimulation of the SNS has been documented to increase bone 
resorption, resulting in reduced cancellous bone mass and microarchitecture, this has 
been primarily attributed to stimulation of beta-2 adrenergic (Adrb2) receptors (78-
80,144).  However, the exact role that beta-1 adrenergic (Adrb1) receptors have in this 
process has not been elucidated.  Dobutamine (DOB), primarily an Adrb1 receptor 
agonist, significantly blunts HU-induced reductions in cortical bone area and cross-
sectional moment of inertia (CSMI), as well as mitigating the decreases in femoral mid-
diaphyseal cortical bone MAR (77).  Furthermore, we have previously demonstrated the 
ability of DOB to inhibit reductions of cancellous bone formation and mitigate losses in 
bone mass at the proximal tibia and femoral neck (145,146).  Demonstrating a direct 
relationship between alterations in osteoblast activity, osteocyte apoptosis, and 
cancellous microarchitecture resulting from Adrb1 agonist administration during 
hindlimb unloading may provide useful insights into underlying mechanisms involved in 
disuse-induced bone loss.      
 Hence, the purpose of the current project was to characterize the independent and 
combined effects of DOB and hindlimb unloading on cancellous bone microarchitecture, 
osteoblast activity, and osteocyte apoptosis.  Furthermore, we sought to define the 
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effects of DOB on the expression of pro- and anti-apoptotic genes within metaphyseal 
bone during normal weightbearing activity and during disuse.  We hypothesized that 
unloading would increase the BAX/Bcl-2 ratio and osteocyte apoptosis in animals 
experiencing metaphyseal bone loss and that DOB administered during HU would 
mitigate deleterious changes in cancellous bone microarchitecture and increase osteocyte 
cell survival. 
 
Materials and Methods 
Animals and Experimental Design  
Thirty-six male Sprague-Dawley rats were obtained from Harlan (Houston, TX) 
at 6 months of age and allowed to acclimate to their surroundings for 14 days prior to 
initiation of the study.  All animals were housed in a temperature-controlled (23 ± 2ºC) 
room with a 12-hour light-dark cycle in an American Association for Accreditation of 
Laboratory Animal Care-accredited animal care facility and were provided standard 
rodent chow (Harlan Teklad 8604) and water ad-libitum.  Animal care and all 
experimental procedures described in this investigation were conducted in accordance 
with the Texas A&M University Laboratory Animal Care Committee rules. 
All animals were randomly assigned to one of two activity groups according to 
body mass on day -1: normal ambulatory cage activity (CC; n=18) or hindlimb 
unloading (HU; n=18).  Each activity group was further divided by random assignment 
to either one daily, bolus intraperitoneal (IP) injection of 4 mg/kg body mass/day 
dobutamine solution (DOB; n=9) or an equal volume of inactive saline solution (VEH; 
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n=9), which was administered within the first 2 hours of the animals’ dark cycle.  
Dobutamine hydrochloride solution (Sigma-Aldrich Corp.) was made daily and stored, 
along with saline solution, at 4ºC until usage.   
Calcein injections (25 mg/kg body mass) were given subcutaneously on 9 and 2 
days prior to sacrifice to label mineralizing bone for histomorphometric analyses.  HU 
animals were anesthetized before removal from tail suspension at the end of the study to 
prevent any weight bearing by the hindlimbs.  At necropsy, both right and left soleus, 
plantaris, and gastrocnemius muscles were excised and wet weights were recorded.  
Right femur were removed, cleaned of soft tissue, and stored at 4°C in 70% ethanol for 
ex vivo CT and pQCT scans and subsequent histomorphormetry, whereas distal right 
femur were stored in paraformaldehyde for paraffin embedding.  Right tibia were 
extracted, cleaned of soft tissue, and immediately frozen in liquid nitrogen and stored at 
-80°C for mRNA analysis.   
 
Hindlimb Unloading 
Hindlimb unloading was achieved by tail suspension as previously described 
(21,105).  Briefly, while the rat was under anesthesia, the tail was cleaned and dried 
thoroughly.  A thin layer of adhesive (Amazing Goop, Eclectic Products, LA) was 
applied to the proximal half of the tail along the medial and lateral sides.  A standard 
porous tape (Kendall, Mansfield, MA) harness was pressed firmly to the glue and 
allowed to dry (~30 min).  A paper clip was used to attach the animal’s tail harness to a 
swivel apparatus on the wire spanning the top of an 18” x 18” x 18” cage.  The height of 
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the animal’s hindquarters was adjusted to prevent any contact of the hindlimbs with the 
cage floor, resulting in approximately a 30° head-down tilt.  The forelimbs of the animal 
maintained contact with the cage bottom, allowing the rat full access to the entire cage.     
 
Ex vivo Micro Computed Tomography (CT) 
Microarchitecture of cancellous bone located in the distal left femur was 
determined using a Skyscan 1172 (Kontich, Belgium) high-resolution desk-top micro-
computed tomography system.  Bones were wrapped in parafilm to prevent drying 
during the scanning.  Scans were obtained using an x-ray source set at 60kV and 167 A 
over an angular range of 180 degrees (rotational steps of 0.40 degrees) with a 6 m pixel 
size.  Projection images were reconstructed using standard Skyscan software.  The 
trabecular bone compartment was segmented from the cortical shell for 50 slices in a 
region ~0.5 mm below the most distal portion of the growth plate for each animal.  
Outcomes variables include bone volume/tissue volume (BV/TV, %), trabecular number 
(Tb.N, m-1), and trabecular thickness (Tb.Th, m).  Values of topological parameters 
were calculated to describe the 3D orientation of the trabecular bone.  Trabecular pattern 
factor (Tb.Pf) representing the amount of concave (plate-shaped bone) and convex 
(rodlike bone) structures was calculated; the higher the Tb.Pf, the more trabecular bone 
is organized in the form of rodlike structures.  The structure modeling index (SMI) was 
measured for the prevalence of platelike or rodlike structures, where 0 represents 
“plates” and 3 represents “rods.” 
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Ex vivo Peripheral Quantitative Computed Tomography (pQCT) 
Scans were performed ex vivo at the distal metaphysis of the left femur with a 
Stratec XCT Research-M device (Norland Corp., Fort Atkinson, WI), using a voxel size 
of 70 μm and a scanning beam thickness of 500 μm.  Daily calibration of this machine 
was performed with a hydroxyapatitie standard cone phantom.  Transverse images of the 
right femur were taken at 4.5, 5.0, 5.5, and 6.0 mm from the distal femur plateau.  A 
standardized analysis for metaphyseal bone (contour mode 3, peel mode 2, outer 
threshold of 0.214 g/cm
3
, inner threshold of 0.605 g/cm
3
) was applied to each section.  
Femora were placed in a 70% ethanol filled vial during the course of the scan.  Values of 
total and cancellous volumetric bone mineral density (vBMD), total bone mineral 
content (BMC) and total bone area were averaged across slices at each bone site to yield 
a mean value.    
 
Histomorphometry Analysis 
 Undemineralized proximal left femur were subjected to serial dehydration and 
embedded in methylmethacrylate (Sigma Aldrich, Inc.; Milwaukee, WI, USA).  Serial 
frontal sections were cut 8 μm thick and left unstained for fluorochrome label 
measurements.  Additionally, 4 μm thick sections treated with von Kossa staining were 
used for measurement of cancellous bone volume normalized to tissue volume 
(%BV/TV),  and osteoid (OS/BS), osteoblast (Ob.S/BS), and osteoclast (Oc.S/BS) 
surfaces as a percent of total cancellous surface.  Adipocyte density was calculated as 
number of adipocytes (Ad.N) divided by the marrow area (Ma.Ar) of the region of 
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measurement.  The histomorphometric analyses were performed by using the 
OsteoMeasure Analysis System, Version 1.3 (OsteoMetrics, Atlanta, GA).  A defined 
region of interest was established ~1 mm from the growth plate and within the 
endocortical edges encompassing 8-9 mm
2 
at x40 magnification.  Total bone surface 
(BS), single labeled surface (SLS), double-labeled surface (DLS), interlabel distances, 
bone volume, and osteoid/osteoclast/osteoblast surfaces were measured at x200 
magnification.  Mineral apposition rate (MAR, μm/day) was calculated by dividing the 
average interlabel width by the time between labels (7 days), and mineralizing surface 
(MS) for cancellous bone surfaces (BS) was calculated by using the formula %MS/BS = 
{[(SLS/2) + DLS]/surface perimeter} X 100.  Bone formation rate (BFR) was calculated 
as (MAR x MS/BS).  All nomenclature for cancellous histomorphometry follows 
standard usage (114). 
 
Osteocyte Apoptosis 
 Distal left femora were fixed in 4% phosphate-buffered formalin for 48 hours at 
4°C and then decalcified in 10% EDTA and 4% phosphate-buffered formalin for 14 
days.  Following decalcification, the distal left femora were embedded in paraffin and 
serial frontal sections were cut 10 μm thick and mounted on slides.  Apoptosis of 
osteocytes were detected by in situ terminal deoxynucleotidyl transferase dUTP nick end 
labeling (TUNEL) using the DNA fragmentation TdT enzyme and fluorescein-dUTP 
label (Roche Diagnostics Corp., Indianapolis, IN) in distal femoral sections 
counterstained with hematoxylin QS (Vector Laboratories; Burlingame, CA).  
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Quantification of osteocytes within individual trabeculae was performed by using the 
OsteoMeasure Analysis System, Version 1.3 (OsteoMetrics, Atlanta, GA).  A defined 
region of interest was established ~1 mm from the growth plate and within the 
endocortical edges encompassing 8-9 mm
2 
at x40 magnification.  Positive staining 
consisted in sections treated with DNase I (Roche Diagnostics Corp., Indianapolis, IN).  
Negative controls consisted of sections which were not incubated with the substrate.  
Apoptotic osteocytes were characterized by TUNEL-stained nucleus with condensed 
chromatin.  The total number of osteocytes (N.Ot) within the region was first counted 
(under normal light), followed by identification of TUNEL+ osteocytes using ultraviolet 
light at 200x magnification.  The number of apoptotic osteocytes was quantified in the 
metaphysis in the same area as for other histomorphometry variables, and was evaluated 
as percentage of total osteocytes.   
 
RNA Extraction and Quantitative Real-Time PCR (RT-PCR) 
Right tibiae metaphyses (proximal 25% of bone) were pulverized using a SPEX 
freezer mill (Model 6750; Metchum, NJ, USA) cooled with liquid nitrogen.  The bone 
powder was suspended and isolated using RNA STAT-60 reagent (Tel-Test, Inc; 
Friendswood, TX, USA) and samples were then centrifuged at 12,000 g for 10 min at 
4°C to precipitate RNA.  Total RNA was isolated, dried, and samples were centrifuged 
at 7,500 g for 5 min.  Samples were dried again, and then dissolved in 
diethylpyrocarbonate (DEPC)-treated water before their concentration was measured 
using a Nano-Drop spectrophotometer (ND-1000; Wilmington, DE, USA) to insure that 
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the A260/A280 (sample purity) ratio was > 1.6.  One g of total RNA from each sample 
was reverse transcribed using the Taqman RT Reagents gene expression assay kit 
(Applied Biosystems, Inc.; Branchburg, NJ, USA) with oligo (dT) primers.  The 
resulting cDNA portions of the Bax, Bcl-2, and 18S sequences were amplified using 
Taqman RT Reagents kit.  RT-PCR analysis was performed using the program SDS 
2.2.2 on using a 7900 HT Fast Real-time PCR System (Applied Biosystems, Inc.; Foster 
City, CA, USA).  For each reaction, 1-4 l of the total RT product was amplified using 
the SYBR green master mix (Applied Biosystems, Inc.; Branchburg, NJ, USA) in a total 
of 20 l reaction volume according to the manufacturer’s standard cycling conditions.  
The –fold change in expression is calculated using a ΔΔCt comparative threshold cycle 
method.  The BAX/Bcl-2 mRNA content ratio was subsequently calculated for each 
sample. 
A negative control, consisting of sterile water, was used in place of RNA and 
ensured no contamination of reaction materials.  18S was used as a housekeeping gene 
control.  Relative expression levels of Bax and Bcl-2, relative to 18S, were calculated.  
Primers specific for Bax and Bcl-2 were designed and purchased from Elim 
Biopharmaceuticals, Inc. (Hayward, CA, USA), and all were previously used in 
published investigations (147,148).  The sequences are as follows: 5’-ATC ATG AAG 
ACA GGG GCC TT-3’ (Bax, forward), 5’-TCT GGA AGA AGA TGG GCT GA-3’ 
(Bax, reverse), 5’-CAG CAT GCG ACC TCT GTT TG-3’ (Bcl-2, forward), 5’-TCT 
GCT GAC CTC ACT TGT GG-3’ (Bcl-2, reverse), 5’-CCT GTA ATT GGA ATG AGT 
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CCA CTT T-3’ (18S, forward), and 5’-ATA CGC TAT TGG AGC TGG AAT TAC C-
3’ (18S, reverse). 
 
Statistical Analyses 
 
All data were expressed as means ± SEM, and their statistical relationships were 
evaluated using the statistical package SPSS (v.15).  Ex vivo CT and pQCT, 
histomorphometry, mRNA content, and osteocyte apoptosis data were analyzed using a 
two-factor ANOVA (drug and gravity).  When a significant main effect was found, 
Tukey’s post-hoc analyses were performed for pairwise comparisons.  For all data, 
statistical significance was accepted at p<0.05. 
 
Results 
Reductions in metaphyseal bone microarchitecture and mass during unloading are 
mitigated with Adrb1 treatment.  To assess changes in cancellous bone 
microarchitecture, ex vivo CT scans were performed on the distal femur.  Unloading 
resulted in significantly lower BV/TV (-33%), Tb.Th (-11%), and Tb.N (-25%) 
compared to ambulatory controls (CC-VEH) (Table 6, Fig 19).  Additionally, both Tb.Pf 
(+54%) and SMI (+21%) were significantly greater than in the CC-VEH group, 
signifying more rod-like trabeculae.  Adrb1 treatment during disuse attenuated these 
changes in cancellous bone microarchitecture.  BV/TV (+29%), Tb.Th (+7%), and Tb.N 
(+21%) were significantly greater in DOB-treated vs. VEH-treated animals subjected to 
disuse.  In addition, SMI was 8% lower in animals administered DOB during HU (vs. 
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Table 6. Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on cancellous bone microarchitecture 
and structure as measured by ex vivo microCT scans.   
 
 
 
Those groups not sharing the same letter for each variable are significantly different from 
each other (p<0.05).     
 
 
 
 
 
 
Table 7. Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on metaphyseal bone mass and 
geometry at the proximal tibia as measured by ex vivo pQCT scans.   
 
 
 
Those groups not sharing the same letter for each variable are significantly different from 
each other (p<0.05).  Group means with no labels are not significantly different.   
        CC   HU 
  VEH DOB 
 
VEH DOB 
BV/TV (%) 20.23 ± 1.36ab 21.05 ± 1.24a 
 
13.46 ± 0.74c 17.42 ± 0.96b 
Tb.Th (mm) 93.10 ± 2.09ab 96.04 ± 1.39a 
 
83.36 ± 1.95c 89.08 ± 1.91b 
Tb.N (mm-1) 2.16 ± 0.12a 2.19 ± 0.11a 
 
1.61 ± 0.08b 1.95 ± 0.09a 
Tb.Pf (mm-1) 8.99 ± 0.77a 8.48 ± 0.61a 
 
13.88 ± 0.56b 11.21 ± 0.71b 
SMI 1.64 ± 0.07a 1.62 ± 0.06a   1.98 ± 0.05c 1.81 ± 0.05b 
       
        CC   HU 
  VEH DOB 
 
VEH DOB 
Total BMC (mg) 12.19 ± 0.42a 12.03 ± 0.29a 
 
10.10 ± 0.25c 10.87 ± 0.27b 
Total Bone Area (mm2) 20.61 ± 0.76 20.25 ± 0.40 
 
19.18 ± 0.61 20.49 ± 0.54 
Total vBMD (mg/cm3) 593.33 ± 11.33a 595.20 ± 11.58a 
 
531.02 ± 16.39b 533.32 ± 11.26b 
Cancellous vBMD (mg/cm3) 329.29 ± 15.27a 320.25 ± 12.12a   245.96 ± 7.77b 271.85 ± 6.50c 
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Fig. 19. Representative three-dimensional CT images of the distal femoral metaphysis 
in dobutamine- (DOB) or vehicle- (VEH) treated rodents during hindlimb unloading 
(HU) or ambulatory cage activity (CC). 
 
 
HU-VEH), indicating less of a shift towards rod-like trabeculae than in HU-VEH rats.  
There was no effect of Adrb1 agonist treatment on trabecular bone microarchitecture in 
weightbearing control rats. 
Hindlimb unloading resulted in significantly reduced total BMC (-17%) and 
vBMD (-11%) and cancellous vBMD (-25%) as compared to ambulatory controls (CC-
VEH; Table 7).  DOB administration during disuse mitigated reductions in two of these 
parameters, resulting in greater total BMC (+8%) cancellous vBMD (+11%) compared 
to VEH-treated animals subjected to disuse (HU-VEH).  There was no effect of either 
unloading or DOB on bone area. Adrb1 agonist administration did not affect 
metaphyseal bone mass or geometry in weightbearing cage control animals. 
 
Adrb1 administration during disuse inhibits reductions in bone formation by 
maintaining osteoblast surface.  Hindlimb unloading produced significantly less 
OS/BS (-66%) and Ob.S/BS (-49%) and greater adipocyte density (+81%) within bone 
marrow as compared to ambulatory controls (Fig 20 A, B, D).  Adrb1 treatment during  
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Fig. 20. Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on cancellous bone measures of 
histomorphometry.  A: Osteoid Surface (OS/BS). B: Osteoblast Surface (ObS/BS). C: 
Osteoclast Surface (OcS/BS). D: Adipocyte Density (N.Ad/Ma.Ar).  VEH groups are 
represented by black bars; DOB groups are represented by gray bars.  Those groups not 
sharing the same letter for each variable are significantly different from each other 
(p<0.05). 
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Fig. 21. Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on cancellous bone measures of 
histomorphometry.  A: Mineralizing Surface (%MS/BS). B: Mineral Apposition Rate 
(MAR). C: Bone Formation Rate (BFR).  VEH groups are represented by black bars; 
DOB groups are represented by gray bars.  Those groups not sharing the same letter for 
each variable are significantly different from each other (p<0.05). 
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HU resulted in significantly greater OS/BS (+158%) and Ob.S/BS (+110%) vs. VEH-
treated animals subjected to HU.  Furthermore, Oc.S/BS was significantly greater in HU-
DOB (+110%) vs. CC-VEH group (Fig 20C).  DOB administration did not affect any of 
these parameters in weightbearing cage controls. 
 Adrb1 treatment during disuse inhibited unloading-induced reductions in MS/BS, 
MAR, and cancellous BFR, which were 52%, 30%, and 67% lower, respectively, in HU-
VEH group as compared to ambulatory controls (Fig 21 A-C).  DOB treatment during 
unloading resulted in significantly greater MS/BS (+2.4-fold), MAR (+55%), and BFR 
(+3-fold) than in vehicle-treated unloaded rats.  Adrb1 agonist administration did not 
affect dynamic histomorphometry measures of bone formation activity in weightbearing 
cage controls. 
 
Increased osteocyte apoptosis during rodent hindlimb unloading is abolished with 
Adrb1 treatment.  In situ nick-end labeling was used to determine the prevalence of 
osteocyte apoptosis within distal femur cancellous bone in rodents subjected to HU 
and/or Adrb1 agonist treatment.  Unloading resulted in a significantly greater percentage 
of apoptotic cancellous osteocytes (+85%) as compared to both ambulatory control 
groups (Fig 22).  DOB-treatment during disuse prevented this increase in osteocyte 
apoptosis, which was 36% lower than in vehicle-treated rats.  There was no difference in 
osteocyte apoptosis between the ambulatory control groups. 
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Fig. 22. Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on cancellous bone TUNEL+ 
osteocytes (%) measured at the distal femur.  VEH groups are represented by black bars; 
DOB groups are represented by gray bars.  Those groups not sharing the same letter for 
each variable are significantly different from each other (p<0.05). 
 
 
Adrb1 treatment during disuse prevents pro-apoptotic state of metaphyseal bone.    
To elucidate the molecular bases underlying the effects of DOB treatment on unloading-
induced gains in osteocyte apoptosis, mRNA content in the proximal tibia was analyzed.  
Unloading significantly enhanced the Bax/Bcl-2 mRNA content ratio in bone as 
compared to the CC-DOB group (Fig 23C).  However, DOB-treated animals subjected 
to unloading did not significantly increase the Bax/Bcl-2 mRNA content ratio in 
metaphyseal bone.  Adrb1 treatment in weightbearing cage control animals did not affect 
Bax/Bcl-2 levels. 
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Fig. 23. Effects of dobutamine (DOB) or vehicle (VEH) administration during hindlimb 
unloading (HU) or ambulatory cage activity (CC) on proximal tibia mRNA content of 
Bcl-2 associated X protein/Bcl-2 ratio (BAX/Bcl-2).  VEH groups are represented by 
black bars; DOB groups are represented by gray bars.  Those groups not sharing the 
same letter for each variable are significantly different from each other (p<0.05).  Group 
means with no labels are not significantly different.   
 
 
Discussion 
The main objective of this study was to determine the effects of a beta-1 
adrenergic agonist (Adrb1), dobutamine (DOB), on metaphyseal bone microarchitecture, 
histomorphometric indices of osteoblast activity, and cell apoptosis.  We hypothesized 
that unloading would result in increased osteocyte apoptosis and metaphyseal bone loss, 
with an associated increase in the BAX/Bcl 2 ratio, and that DOB administered during 
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HU would mitigate deleterious changes in cancellous bone microarchitecture and 
increase osteocyte cell survival. 
Most strikingly, our data confirm that dobutamine treatment during unloading 
inhibited reductions in cancellous bone formation, resulting in attenuated losses in 
cancellous bone mineral density (vBMD) and bone volume (BV/TV).  Dobutamine 
treatment prevented increased cancellous osteocyte apoptosis and may have mitigated 
the increase in Bax/Bcl-2 levels evidenced during disuse.  We found no effect of DOB 
treatment on any of these outcomes when it was administered to rats experiencing 
normal ambulatory cage activity.  Taken together, these data demonstrate the dynamic 
role that beta-1 adrenergic agonist signaling has on maintaining cancellous bone during 
periods of reduced weightbearing or unloading. 
Data from this experiment demonstrate an overall increase in forming and 
resorbing surfaces with dobutamine treatment during unloading.  DOB administration 
resulted in significantly greater osteoblast (+110%) and osteoid (2.6-fold) surface within 
cancellous bone of the distal femur as compared to vehicle-treated hindlimb unloaded 
rodents (Fig 20 A-B).  Most strikingly, these increases in osteoblast surface were 
accompanied by 2.4 to 3-fold greater mineralizing surface and bone formation rate (Fig 
3 A, C) and 55% greater mineral apposition rate (Fig 21B) vs. HU-VEH group.  
Additionally, dobutamine treatment during unloading resulted in significantly greater 
osteoclast surface (+110%) compared to vehicle treated ambulatory controls (Fig 20C). 
Only one investigation each has assessed the effects of Adrb2 receptor agonist 
treatment on cancellous bone cell activity using ovariectomized (OVX) rodents or mice 
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subjected to unloading.  Salbutamol, a β-2 adrenoreceptor agonist, administered to OVX 
rodents did not significantly alter osteoblast or osteoclast activity as compared to 
untreated estrogen deficient rats (80).  However, salbutamol-treated OVX animals 
significantly increased both active bone resorbing and forming surfaces as compared to 
sham-controls.  Mice administered isoproterenol (equally stimulating β-1 and β-2 
adrenergic receptors) during unloading exhibit significant reductions in cancellous 
BV/TV, attributable to significantly lowered bone formation (149).  Numerous 
investigations have demonstrated that Adrb2 receptor agonist administration in 
weightbearing rats reduces net bone formation by inhibiting osteoblast and increasing 
osteoclast differentiation.  Takeda et al. (75) showed that isoproterenol, a non-specific β-
adrenergic agonist, decreased cancellous BV/TV by significantly reducing osteoblast 
number and bone formation rate (-24-42% vs. controls).  Furthermore, salbutamol 
treatment induced significant reductions in both tibia and femur cancellous bone volume 
as a consequence of significantly increased osteoclast surface (144).  Deletion of all 
adrenergic receptors in skeletally mature mice results in even greater reductions in distal 
femur bone formation (-63% vs wild-type littermates) (83).  Taken together, these data 
suggest opposing roles of Adrb1 and Adrb2 receptors on osteoblasts, and that, when 
activated, Adrb2 receptors inhibit osteoblast activity, whereas signaling via Adrb1 
receptors promotes bone formation.    
 Administration of β-2 adrenergic agonists results in significant and deleterious 
modifications to cancellous bone microarchitecture.  Both salbutamol and clenbuterol 
treatment significantly reduces metaphyseal bone volume by reducing Tb.Th and 
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increasing Tb.Sp, resulting in increased rodlike trabecular structures (78,79,144).  
Trabecular microarchitecture was similarly affected by concurrent Adrb2 administration 
in OVX rats (80).  Data from our current investigation provide evidence for an opposing 
effect of Adrb1 treatment in the context of disuse.  Dobutamine administration 
significantly mitigated unloading associated reductions in BV/TV by attenuating reduced 
Tb.Th and Tb.N (Table 6).  Furthermore, hindlimb unloading resulted in a prevalence of 
more rod-like trabecular structures within the distal femur, which change was attenuated 
with dobutamine treatment.  In contrast to the aforementioned deleterious effects of β-2 
adrenergic agonists, Adrb1 administration to rats allowed normal cage activity did not 
produce any significant alterations in cancellous bone microarchitecture. 
Reductions in metaphyseal bone mass and structure during hindlimb unloading 
have been characterized by immediate increases in osteocyte and osteoblast apoptosis.  
Recent data have demonstrated a significant increase in cancellous osteocyte apoptosis 
in unweighted proximal tibiae by day 3 of HU, persisting for up to 18 days after disuse 
(106,107,120).  An in vitro study using isoproterenol, an Adrb agonist (equally 
stimulating Adrb1 and Adrb2 receptors), demonstrated beta-adrenergic stimulation to 
have anti-apoptotic effects on cultured osteoblasts (131).  Data from our investigation 
provides further evidence that Adrb1-signaling protects osteocytes from apoptosis, as 
dobutamine treatment during unloading inhibited disuse-induced increases in osteocyte 
apoptosis in cancellous bone of the distal femur (Fig 22A).  Furthermore, our current 
investigation implies the ability of Adrb1 agonist treatment to potentially mitigate 
associated increases in Bax/Bcl-2 mRNA content of metaphyseal bone (Fig 23C), 
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although these data are not definitive.  In unloaded animals treated with vehicle, the 
trend towards increased Bax/Bcl-2 mRNA content of disuse-sensitive cancellous bone 
was attributable to a significant increase in Bax and no effect on Bcl-2 mRNA.  While 
this finding is in agreement with data of Dufour et al. (120), the earlier study found that 
the HU-induced increased Bax/Bcl-2 ratio was due to decreased Bcl-2 mRNA content.  
Data from our current study provide preliminary evidence for the role of adrenergic 
signaling in inhibiting apoptosis of mechano-sensing cancellous osteocytes, possibly by 
mitigating increases in Bax mRNA levels during disuse.   
 Previously we demonstrated that dobutamine treatment during unloading 
significantly mitigated longitudinal reductions in proximal tibia total vBMD by 
maintaining bone formation (145,146).  Furthermore, data from these studies showed 
that effects of Adrb1 treatment occurred mainly in cancellous (and mixed bone sites) and 
not cortical bone compartments of unweighted tibia and femur.  However, lacking 
details about alterations in bone cell activity and cancellous bone microarchitecture, we 
were unable to adequately describe the effects of Adrb1 administration during normal 
and reduced gravitational loading.  Data from this current study are in agreement with 
our previous studies, demonstrating that dobutamine treatment maintains cancellous 
bone formation during disuse.  Furthermore, similar to our previous study, we 
demonstrate that Adrb1 receptor agonist administration mitigates losses in cancellous 
vBMD at the distal femur.   
 Hindlimb unloading increases adipocyte number, while simultaneously inhibiting 
osteoblast differentiation, resulting in increased adipocyte number and volume and 
123 
 
 
reducing bone mass and strength at the proximal tibia (150-152).  Furthermore, beta-
adrenergic stimulation has been shown to increase bone marrow adipocyte lipolysis 
(153).  Interestingly, we demonstrated that dobutamine treatment mitigated unloading 
associated increases in marrow area adipocyte density (Fig 20D).  While we did not 
measure adipocyte differentiation, data from our current study provide preliminary 
evidence that Adrb1 agonist administration during disuse may reduce adipocyte 
proliferation and result in increased osteoblast formation and activity (Fig 20, 21). 
Knock-out mouse models have demonstrated the potentially unique effects of β-1 
and β-2 adrenergic receptors on osteoclasts and osteoblasts, ultimately affecting 
cancellous bone mass and microarchitecture.  Adrb2 and Adrb1 receptor knock-out (KO) 
mice have demonstrated a high and low bone mass phenotype, respectively, whereas 
Adrb1/2 receptor double-KO mice exhibit a marked reduction in cancellous BFR vs. 
wild types (67,82,127).  Furthermore, complete deletion of all 3 Adrb receptors results in 
a significant reduction in bone formation, although trabecular microarchitecture and 
bone volume remain unchanged (83).  Bonnet and colleagues (82) demonstrated that 
Adrb1 receptor-deficient mice do not respond to mechanical loading, whereas Adrb2 
receptor KO mice and wild-type littermates were found to respond normally.  Taken 
together, these data suggest that the higher bone mass phenotype in Adrb2 receptor KO 
mice may be caused by enhanced β-1 adrenergic receptor activity, stimulating bone 
formation in the absence of the inhibitory effects of β-2 adrenergic receptors on 
osteoblasts.  Therefore, delineating the effects of Adrb1 receptor stimulation on disuse-
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sensitive cancellous bone during reduced mechanical loading is important to defining the 
underlying mechanisms responsible for bone loss. 
There were a few limitations of the current study.  To fully elucidate the 
individual and, potentially, combined effects of disuse and Adrb1 receptor treatment on 
adrenergic receptors, immunohistochemistry analysis of osteoblast and osteoclast 
expression of Adrb1 and Adrb2 within weightbearing cancellous bone would be useful 
in elucidating mechanisms responsible for the effects demonstrated in this study.  
Additionally, although we did quantify osteocyte apoptosis within cancellous bone of the 
distal femur, we were unable to describe the effects of Adrb1 treatment during unloading 
on osteoblast or osteoclast apoptosis.   
In conclusion, β-1 adrenergic receptor agonist treatment during unloading 
significantly impacted metaphyseal bone and inhibited associated increases in apoptosis.  
DOB administration during disuse abolished reductions in cancellous bone formation 
and resulted in significantly greater bone volume, trabecular thickness, and trabecular 
number as compared to vehicle-treated animals.  Furthermore, Adrb1 treatment inhibited 
increased prevalence of apoptotic osteocytes and may have maintained Bax/Bcl-2 levels 
within cancellous bone during disuse.  Similar to our previous findings, we demonstrate 
no deleterious effects of Adrb1 agonist treatment on cancellous bone during normal 
ambulation.  These data further define the role that β-adrenergic receptors have in 
mediating bone’s response to periods of disuse or unloading.  However, further studies 
are necessary to determine the precise mechanisms involved with adrenergic signaling in 
bone during disuse.  
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CHAPTER VII 
CONCLUSIONS 
 
 The ultimate goals of the first two studies were to determine the role that high 
intensity muscle contractions and bisphosphonate treatment, initiated during an extended 
period of mechanical unloading, have on maintaining disuse-sensitive cancellous bone.  
Eccentric- and combined isometric+eccentric-based simulated resistance training (SRT) 
protocols were used alone or in combination with alendronate (ALEN) treatment and 
compared to unloaded controls.  The second two studies were completed to determine 
the role that beta-1 adrenergic (Adrb1) agonist administration has on metaphyseal bone 
during disuse.  Dobutamine (DOB), an Adrb1 receptor agonist, was administered during 
28-day hindlimb unloading (HU) or during normal ambulation.  Measurements of bone 
mass and geometry (via pQCT), metaphyseal bone microarchitecture and structure 
(CT), dynamic and static histomorphometry, bone biomechanical properties (reduced 
platen compression and 3-point bending tests), osteocyte apoptosis, and mRNA content 
of specific genes (real-time quantitative polymerase chain reaction) were used to assess 
the efficacy of these different treatments. 
Data from these investigations document that (1) high-intensity, eccentric-based 
resistive exercise, begun early during the period of unloading, can prevent the loss of 
bone mass and muscle strength routinely observed during a period of disuse or exposure 
to microgravity; (2) ALEN treatment, when combined with high-intensity muscle 
contractions during disuse, significantly reduces the anabolic response of cancellous 
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bone to SRT; (3) mechanical loading (due to muscle contractions) and ALEN treatment 
(acting independently and in combination) inhibit disuse-associated increases in 
cancellous osteocyte apoptosis; (4) Adrb1 receptor agonist administration during HU 
attenuates reductions in metaphyseal bone mass by effectively maintaining cancellous 
bone formation; (5) DOB administration during rodent HU inhibits disuse-associated 
increases in osteocyte apoptosis by preventing increases in the ratio of Bax/Bcl-2 mRNA 
content within metaphyseal bone; (6) the mitigation of reductions in metaphyseal bone 
microarchitecture and cancellous bone mineral density in DOB-treated animals, as 
compared to unloaded  controls, is primarily due to greater increases in bone formation 
than increased resorption; (7) beta-1 adrenergic receptor agonist administration during 
normal ambulation is not deleterious to bone. 
The first two studies provide preliminary data on the impact that resistance 
exercise has on maintaining bone mass and strength during periods of disuse or reduced 
weightbearing activity.  Recent data has demonstrated the effectiveness of mechanical 
loading to significantly diminish sclerostin (SOST) expression within osteocytes using 
immunohistochemistry (IHC) techniques (154).  SOST, a key inhibitory regulating 
protein in bone, as well as canonical Wnt/β-catenin signaling within osteoblasts may be 
crucial mediators of unloading-related reductions in bone mass and formation associated 
with disuse.  Future, mechanistically-driven investigations are necessary to outline the 
effects of resistive exercise during unloading on potential signaling pathways so that 
effective interventions targeting these proteins can be established and applied to other 
models attempting to address the mechanisms responsible for osteoporosis. 
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The second two studies provide preliminary data on the effects of Adrb1 receptor 
agonist administration during HU and demonstrate the basic cellular mechanisms 
responsible for the positive effects of DOB treatment.  Further research defining the 
exact role of disuse on Adrb2 and Adrb1 receptors within osteoblasts and osteoclasts is 
necessary to help explain data from these current investigations and can be accomplished 
with in situ immunohistochemistry.  Additionally, Adrb1receptor knock-out mice studies 
would help explain the differentiating results on cancellous bone demonstrated in DOB 
treatment during disuse and normal ambulation.  Data from these investigations can help 
further elucidate those mechanisms responsible for bone loss and potentially assist in 
determining the exact role of beta-adrenergic signaling within bone cells. 
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 APPENDIX A 
TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE dUTP NICK END 
LABELING (TUNEL) ASSAY FOR PARAFFIN-EMBEDDED BONE SECTIONS 
 
Melt paraffin on slides 
You can complete up to 18 slides (with duplicate bone slices on each slide, of course) 
per day; each fluorescein in-situ cell death kit (Roche Diagnostics, Inc.; Indianapolis, 
IN) allows for only 50 samples (25 slides). This procedure will take you around 3-4 
hours.  Place slides in glass holders (empty bottom) and put in a 56-58°C oven for 10-15 
minutes, or just until the paraffin melts.  After paraffin melts, immediately turn oven 
down to 31°C. 
 
1. Deparaffinize slides 
 
Before the paraffin hardens dehydrate the slides in the following graded series of xylenes 
and alcohol (thus, the slide holders must physically fit in the ~ 300 ml jars that hold 
these liquids): 
 
1. Xylene 5 min 
2. Xylene 5 min 
3. 100% ethanol 3 min 
4. 100% ethanol 3 min 
5. 95% ethanol 3 min 
6. 70% ethanol 3 min 
 
Don’t reuse these solutions! 
 
2. Rehydrate sections with 0.3% H2O2 (594 ml DI water, 6 ml 0.3% H2O2) in DI water 
for 30 minutes. Use the same glass slide holders as before and quench in 300 ml jars. 
 
3. Make “wells” with Liquid Blocker pen (Accurate Chemical and Scientific Corp, 
Westbury, NY) around each bone slice.  It is very important that these wells will keep 
the fluids and don’t leak.  Take your time when you are doing this step, but make sure 
that the bone samples are well-hydrated. 
 
3. Incubate tissue section for 15-30 minutes at 21-37°C with Proteinase K recombinant 
(PCR Grade; Roche Diagnostics, Indianapolis, IN) in oven.  Proteinase K has been 
aloquated out in 1 ml vials in a concentration of 20 mg/ml.  To make up Proteinase K 
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solution for TUNEL assay, thaw out aliquot and remove 2 vials of 10 l; dilute 10 l in 
1 ml of 10mM Tris-HCl (2 vials total).   
 
After incubation is complete place a steel pan filled with dd H2O and 3 drops of Clear 
Bath Algicide (NWR International; Polyscience, Niles, IL) in bottom of oven 
(humidifies oven).   
 
4. Rinse slides 2x with freshly made PBS (make with Distilled H2O). 
 
5. Remove TUNEL reaction mixtures from ice.   
  
 a) Remove 100 l Label Solution (vial 2) for two negative controls. 
b) Add total volume (50 l) of Enzyme Solution (vial 1) to remaining 450 l 
Label Solution in vial 2 to obtain 500 l of TUNEL reaction mixture. 
c) Mix well to equilibrate components. 
d) Remember to complete 1 positive control (DNase I recombinant) for each 
TUNEL kit.  To make DNase I recombinant (Roche Diagnostics, Inc.; 
Indianapolis, IN): 1) combine 0.788g Tris-HCl (157.6g/M; Sigma, St. Louis, 
MO) with 100mL Di H2O2, 2) add 1 mg/ml BSA (Bovine Serum Albumin; in this 
case, add exactly 0.1g BSA because we are using 150 ml solution), 3) combine 
6.7 l of DNase I (concentration is 10 U/l; need concentration of 1500 U/ml; 
have 10,000 units in 1 ml; therefore, use 6.7 l DNase I) with 150 l of Tris-
HCl/BSA solution.   
 
6. Rinse slides 2x with PBS (place slides in PBS-filled jar for 2 minutes); subsequently 
dry area around samples with cotton-tipped swab. 
 
7. Add 50 l TUNEL reaction mixture on samples (NOTE: for negative control, add 50 
l Label Solution each instead of TUNEL reaction mixture; for positive control, add 50 
l DNase I solution, then add 50 l TUNEL reaction mixture).  
 
8. Incubate slides in a humidified atmosphere for 60 min at 37°C. 
 
9. Rinse slides 3x with fresh PBS. 
 
10. Counterstain with 1 ml drop of hematoxylin (Hematoxylin QS; Vector Laboratories; 
Burlingame, CA) for 10-15 seconds of exposure (less time if stain is too bright). 
 
11. Rinse slides for 3-5 seconds under faucet with tap water and return to slide holder. 
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12. Immediately coverslip one slide at a time under dark conditions until all slides are 
complete, and place slides in a box.  Do not allow for extended UV light exposure by 
slides (i.e. sunlight)!  This light will fade fluorescent labeling of cells & inhibit accurate 
measurement of TUNEL+ cells. 
 
13. Measure positive & negative controls first under UV light (SWB) at x200 or x400 
magnification to ensure quality of solutions.   
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